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Abstract
My dissertation explores the interactions between the various agents in the pharma-
ceutical industry and how they are affected by changes in health care policy. In my
work, I examine innovation and competition among new brand drugs and the value
of prescription drug insurance after patent expiration.
The second chapter of my dissertation empirically assesses the trade-off between
patent breadth and patent length, a topic that has attracted significant theoretical
but little empirical attention. I estimate a model of pharmaceutical demand and
supply that incorporates insurance and advertising for the antidepressant market.
Using these estimates, I consider the potential welfare effects of giving some of the
most important product innovations broader but shorter patents, which increases the
market power that these innovators have in the short-run but also allows for more
rapid entry by generics. My results indicate that in this setting broader patents
could increase total welfare by more than 9%, mostly through savings in insurer
expenditures. These results are robust to endogenizing the entry of other branded
drugs.
In the third chapter, which stems from research done jointly with Peter Ar-
cidiacono, Paul Ellickson, and David Ridley, I use data from the pharmaceutical
industry to estimate demand and supply for prescription drugs across both insured
and uninsured consumers, allowing for consumer preferences organized into discrete
types. I account for an important characteristic of health care markets: the price
iv
paid by insured consumers (copayment) is typically much smaller than the price re-
ceived by the manufacturer. This analysis highlights how generic-drug availability
differentially affects insured and uninsured consumers. In particular, generic entry
disproportionately benefits insured consumers, at least in the first year to two years.
The fourth chapter in my dissertation extends the analysis in Chapter 2 to allow
for a more generalized framework. In Chapter 2, the first pharmaceutical product
innovation that enters a therapeutic class is assumed to be high-value while those
innovations that follow are assumed to provide relatively little, if any, added thera-
peutic value beyond the first. Using the same data and demand model estimates, I
consider the potential welfare effects of allowing these later to be considered high-
value products and providing them with greater patent breadth and shorter patent
length. My results indicate that in this setting, the modified patent policy could
still increase total welfare by more than 8%, mostly through savings in insurer ex-
penditures. These results are also robust to endogenizing the entry of other branded
products.
v
This dissertation is dedicated to my family.
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1Introduction
My dissertation explores the interactions between the various agents in the pharma-
ceutical industry and how they are affected by changes in health care policy. The
complexity of the pharmaceutical markets, in part, stems from the many agents
involved: brand innovators, generic imitators, pharmacies, insurers, doctors, and
patients. The interactions between these agents are often complex and imperfectly
observed by the rest of the market. Understanding these interactions is made all the
more important by the fact that U.S. pharmaceutical expenditures were the fastest
growing component of the total national health expenditure in the last two decades
and reached a 10% share in 2010 ($260 billion). Moreover, health care expenditures
have received a great deal of public attention recently, specifically with the goal of
reducing costs. In my work, I examine innovation and competition among new brand
drugs and the value of prescription drug insurance after patent expiration.
In the second chapter, I use data from the pharmaceutical industry to provide
the first empirical assessment of the trade-off between patent breadth and patent
length. These are the standard levers of patent policies, where patent breadth is a
measure of the scope of protection and patent length specifies the duration that this
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protection can be enforced. While the theoretical literature provides some guidance
on what combination of these levers might be optimal, there has been relatively little
work using data to measure the possible gains to alternative breadth-length designs.
To implement my analysis, I use a structural model of demand and supply, which
allows me to identify how changing patent breadth and length would impact social
welfare. Additionally, my analysis accounts for the effect that health insurance has
on consumers’ prescription drug prices. As insured consumers pay only a fraction of
the full retail price for their pharmaceutical products and insurers subsidize the rest,
it is important to account for how this would affect their price sensitivities.
Focusing on the market for antidepressants, I consider two policy experiments.
For the first, I assume that the first product to enter a therapeutic class is a ground
breaking, high-value product, while later entrants into the class provide relatively
little, if any, added therapeutic value beyond the first. I then modify the patent of this
first product to address the debate in the pharmaceutical policy literature about the
value of limiting the development of later entrants. Specifically, I expand the patent
breadth and limit the patent length of the groundbreaking antidepressant, Prozac,
in order to temporarily delay the entry of the subsequent products in the same
therapeutic class into the market. I find that the total social impact of this modified
policy is a gain of more than 9%, mostly through savings in insurer expenditures.
The second counterfactual extends the first, by allowing the innovators of the
later products to anticipate the impact of the modified policy and reoptimize their
entry decisions during their respective drug development processes. Those innovators
that abandoned their drugs save their remaining investment expenditures. I find that
while some later innovators would still proceed with their drug developments, others
are likely to abandon their innovations, depending on their specific development
costs. However, the net social welfare effect is still large and positive. Overall, this
research indicates the potential for meaningful social gains from exploring these types
2
of modified patent policies for industries with a slow and costly innovation process.
The third chapter stems from research done jointly with Peter Arcidiacono, Paul
Ellickson, and David Ridley, and focuses on exploring how generic-drug availability
differentially affects insured and uninsured consumers. Simple logic suggests that
generic drugs particularly benefit uninsured consumers. However, I show that this
logic might be wrong, because generic prices fall slowly for uninsured consumers,
while insurance copayments fall immediately upon generic entry. Being labeled a
generic and having a price below the branded drug are sufficient for the insurance
copayment to fall, while it is only through competition that the generic price falls.
Hence, at least initially, generic entry disproportionately benefits insured consumers.
For our analysis, I estimate demand and supply for prescription drugs across both
insured and uninsured consumers, allowing for consumer preferences organized into
discrete types. We account for an important characteristic of health care markets:
the price paid by insured consumers (copayment) is typically much smaller than
the price received by the manufacturer. Our analysis highlights how generic-drug
availability differentially affects insured and uninsured consumers. In particular,
generic entry disproportionately benefits insured consumers, at least in the first year
to two years.
While this chapter does not explicitly consider policy, estimates from our models
of demand and supply allow for the examination of policy experiments. Among the
potential experiments is examining the welfare impact of the insurance expansion
under the Affordable Care Act (ACA or “Obamacare”), as it impacts consumers,
producers, and insurers. Insurance expansion creates possible spillovers for manu-
facturers. In turn, this creates greater incentives for drug producers to enter the
market.
The fourth chapter in my dissertation provides an extension of Chapter 2. Specif-
ically, I relax the assumption that later entrants into a therapeutic class provide rela-
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tively little, if any, added therapeutic value beyond the first. A notable need for this
extension is Lipitor, which was the sixth innovation to enter the therapeutic class of
statins (cholesterol drugs), but is the best-selling drug of all time. The highly suc-
cessful drug Zoloft provides another example as the second antidepressant to target
the serotonin reuptake mechanism in the body. In this chapter, I ask the following
question: Do the results from Chapter 2 still hold when an innovation that is not
first-in-class is considered to be high-value and provided with the modified patent?
In order to implement my analysis, I use estimates from the static model of de-
mand presented in Chapter 2. The model allows for the quality of products to be
determined by consumer preferences. It is then assumed in the policy experiments
which products are high-value innovations and which are not. I consider two policy
experiments, which correspond to the two experiments in Chapter 2. The experi-
ments expand the patent breadth and limits the patent length of multiple high-value
innovations. Effectively, this works by simply tranferring the expanded breadth from
an earlier high-value product to a later one that proved to provide significant added
therapeutic value. I find that while the net social welfare gains in both policy ex-
periments are lower than those presented in Chapter 2, they are still positive and
large. Therefore, these results indicate the potential for meaningful social gains from
exploring modified patent policies in a more realistic setting.
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2Patent Breadth Versus Length:
An Examination of the Pharmaceutical Industry
2.1 Introduction
Innovation is a primary source of growth for social welfare. Often, innovation is
spurred by patents, which confer market exclusivity to innovators. The aim of patent
policy is to maximize social welfare by balancing the two competing forces that cor-
respond to this exclusivity: the increasing incentive to innovators and the increasing
social cost from market distortions. The standard levers of these policies are patent
breadth (the scope of protection), which restricts competitive imitation, and patent
length, which specifies the amount of time the protection can be enforced. While the
theoretical literature provides some guidance on what combination of these levers
might be optimal, there has been relatively little work using data to measure the
possible gains to alternative breadth-length designs. In this chapter, I use data from
the pharmaceutical industry to provide the first empirical assessment of the trade-off
between patent breadth and patent length.
The U.S. pharmaceutical industry is a particularly relevant setting in which to
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examine modifications to patent policy. Pharmaceutical companies rely heavily on
patents to safeguard innovator profits and there has been an on-going debate over the
possible need for innovation-related policy reform.1 The debate revolves around the
idea that there are two types of pharmaceutical product innovations: those that in-
volve groundbreaking new therapies and major improvements over existing products
and much more incremental innovations that provide little, if any, added therapeutic
benefit.2 Despite this difference, both types of innovations require substantial invest-
ment to develop (DiMasi et al., 2003). Critics of the current policy argue that this
latter group of innovations, often referred to as “me-too” products, provide insuffi-
cient social benefits to warrant these substantial costs and contribute to the rising
costs of health care.3 My work directly informs this debate by asking the following
question: What is the impact on the market of giving some of the most impor-
tant product innovations broader but shorter patents, which limit the profitability
of “me-too” products but allow for more rapid entry of generics?
To estimate the welfare implications of modifying patent breadth and length,
I employ a structural approach. While historically there have been a number of
patent policy modifications significant to the pharmaceutical industry, none of these
occurred in recent decades. Taking a structural approach allows me to identify how
changing patent breadth and length would impact social welfare. Existing theoreti-
cal work points out that product substitutability and market competitiveness affect
the optimal balance of patent breadth and patent length. I begin by estimating a
model of demand and supply with differentiated products. My framework accounts
for the effect that health insurance has on consumers’ prescription drug prices. For
1 This debate is primarily targetted to innovation of small-molecule drugs, as opposed to biologics,
which differ in how innovation and patenting are conducted. For this reason, this chapter focuses
exclusively on small-molecule drug markets.
2 This distinction is also recognized by other countries, including Canada (Lexchin, 2006).
3 See Kessler et al. (1994), Relman and Angell (2002), Hollis (2004), Angell (2005), Goozner
(2005), and Gagne and Choudhry (2011).
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pharmaceutical products, insured patients pay only a fraction (the copay) of the full
retail price. Therefore, ignoring this feature runs the risk of underestimating con-
sumers’ price sensitivities and distorting the results of any subsequent analyses that
build on these estimates. Using the model estimates, I then examine the implication
of the modified policies on welfare through counterfactual simulations.
For a patent policy to be feasible, the measure of patent breadth must be defined
in such a way that it is known to the market and independent of any decisions
made by the firms. Hence, in a practical setting, there are only a limited number of
available levels that can be used for breadth. I consider a specific set of modifications
that are available for the pharmaceutical market. Given that patent breadth in the
pharmaceutical industry is already specified in the narrowest feasible terms, the basic
counterfactual expands the breadth of a groundbreaking (high-value) drug’s market
exclusivity by temporarily blocking from the market subsequent drugs that provide
little, if any, added value (“me-too”s). This expansion, which leads to increased
profits for the high-value innovator, is balanced by a reduction in patent life in order
to make her indifferent between the two policy settings. Once the patent for the
high-value drug has expired, the “me-too” drugs as well as the generic versions of
the high value drug are allowed to enter the market. Effectively, this counterfactual
delays market entry of “me-too” drug innovations and advances generic entry on the
high-value drug. In this way, I propose to shift incentives, and consequently R&D
investment, away from “me-too” innovations to those that are greater in value. I
then examine the net impact on drug producers (innovators and manufacturers),
consumers, insurers, and overall social welfare.
My analysis focuses on the market for antidepressants. Antidepressants consti-
tute one of the best selling pharmaceutical markets of the past two decades and
are exclusively comprised of prescription drugs. I use data containing monthly U.S.
pharmaceutical prices and quantities for retail prescription sales as well as national
7
advertising expenditures, for the period 1991 to 2010. These data capture the evolu-
tion of the dominant therapeutic drug class, from the pioneer molecule to the entry
of subsequent molecules and the eventual generic entry on nearly all of the top selling
molecules.
I estimate own-price elasticities, based on consumer copays, in the range between
-1.6 and -3.2. As expected, I find much higher cross-price elasticities among drugs
that are similar in the way they function versus those that are not. This suggests
that if the modified policy is targeted to a specific grouping, it will have limited
impact on products outside of that grouping.
Using estimates from the static models of demand and supply, I consider two
policy experiments. The first modifies the patent of the first-in-class groundbreak-
ing drug to address the debate in the pharmaceutical policy literature about the
value of limiting the development of “me-too” drugs.4 Specifically, I expand the
patent breadth and limit the patent length of the groundbreaking antidepressant,
Prozac, in order to temporarily restrict the subsequent “me-too” products in the
same therapeutic class from entering the market. I find that the patent life of Prozac
is shortened by nearly six years (70 months). Additionally, the $3.8 billion in lost
profits (64%) suffered by “me-too” innovators is overshadowed by the $10.2 billion
in savings (14.4%) realized by insurers. Finally, consumers experience a welfare gain
of $312 million (1.6%) under the modified framework. The total social impact of this
modified policy is a gain of more than $10.6 billion (9.4%).
The second counterfactual extends the first, by allowing the “me-too” innovators
to anticipate the impact of the modified policy and reoptimize their entry decisions
during their respective drug development processes. Those innovators that aban-
doned their drugs save their remaining investment expenditures. I find that while
4 In this chapter, I assume that all products that enter after the first-in-class are “me-too”s. At the
end of the chapter, I discuss on-going work in which this assumption is relaxed and these subsequent
entrants can be recognized as high value products.
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Zoloft would always proceed through Phase III clinical trials and onto the market,
Paxil and Celexa would do so with probabilities of only 48.5% and 88%, respec-
tively. The net effect on producers is a slight gain ($178 million or 1.1%) due to
the expenditures saved by entry re-optimization. In cases where the products do
not enter the market, consumers lose the value of their entry as well as the generics
that would have followed on each molecule. However, this loss is still overshadowed
by the gain of earlier generic entry on Prozac’s molecule, fluoxetine ($194 million or
1%). Insurers realize even greater gains ($10.9 billion or 15.4%) as consumers who
would have otherwise purchased Paxil and Celexa, turn to generic fluoxetine instead.
The net social welfare effect sums to $11.4 billion (10.1%). These results indicate
the potential for meaningful social gains from exploring modified patent policies.
While this is the first empirical study of the tradeoff between patent breadth and
length, some aspects of the problem are not addressed. For example, this chapter
does not try to address the question of whether initial innovators should be rewarded
more generous patents; instead, like most of the theory literature, it considers how
to give the initial innovator a fixed reward. Additionally, the analysis includes only
a limited range of dynamics. While “me-too” innovators are allowed to reoptimize
their entry decisions, the decisions of other market participants are assumed to be
exogenous and held fixed. Finally, all follow-on products that enter prior to Prozac’s
patent expiration are assumed to be “me-too”s. At the end of the chapter, I discuss
ongoing work that seeks to address this last limitation.
I proceed in the chapter by first presenting the related literature, which is com-
prised of the theoretical work on optimal patent design as well as the empirical work
aimed at quantifying the effects of competition and social welfare in the pharmaceuti-
cal industry. In Section III, I then describe the salient features of the pharmaceutical
industry, the data sets, and the market for antidepressants. I present the static mod-
els of demand and supply in Section IV and the estimation procedure in Section V.
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In Section VI, I describe the results and their implications for the counterfactual sim-
ulations. Finally, I implement the counterfactual simulations to measure the welfare
implications on consumers, insurers, and producers (innovators and manufacturers)
in Section VII.
2.2 Related Literature
This section reviews the relevant literature and contrasts it with the policy simu-
lations in this chapter. The theoretical literature has provided important insights
on the underlying determinants of optimal patent policy, particularly with regard
to the combination of patent breadth and patent length. Despite the theoretical
foundation, relatively little applied work has considered this trade-off.
2.2.1 Theory of Optimal Patent Design
Substantial theoretical work has been done to examine incentives to innovation and
the social value of patents.5 The segment of the literature relevant to my work an-
alyzed how the balance between patent breadth and patent length influences social
cost for a given stand-alone product innovation.6 These papers employed stylized
models to highlight the importance of the market structure and the shape of the de-
mand curve in determining optimal patent policy. The market structure is broadly
defined to include whether products are differentiated, the number of potential inno-
vators, and the nature of innovation and production costs.7 For a given innovation,
5 For a comprehensive review of this literature, see Rockett (2010).
6 Stand-alone innovation refers to the final market product being composed of one innovation.
Other segments of the literature have considered products that are comprised of a combination of
different innovations (Scotchmer, 1991; Green and Scotchmer, 1995; O’Donoghue et al., 1998; Bessen
and Maskin, 2009) and optimal patent policy with different combinations of policy levers, including
patent length alone (Nordhaus, 1969; Scherer, 1972; Nordhaus, 1972), patent length with compulary
licensing (Tandon, 1982), patent renewals (Cornelli and Schankerman, 1999), and menues of patents
(Cornelli and Schankerman, 1999; Hopenhayn and Mitchell, 2001).
7 The literature has considered various settings, including: one innovator and many potential
imitators in homogeneous products markets (Gilbert and Shapiro, 1990; Gallini, 1992); multiple
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the shape of the demand curve reflects consumers’ product substitution behavior.
The greater this substitutability, the more sensitive consumers will be to a product’s
price increases and thus, the lower the price that will maximize the innovator’s profit.
In this way, the shape of the demand curve defines how much profit the patentholder
can extract under a given policy.
Many of the relevant papers in this literature share two common features in their
approach to optimal patent policy. First, they examined the optimal combination of
patent breadth and length that guarantees an innovator a given reward, rather than
determine what that award should be.8 Thus, in a given market, the optimality of
a patent policy lies in its ability to minimize social costs while providing sufficient
incentive to the innovator. The second key feature is the assumption that demand is
independent of patent policy. This means that consumers are expected to purchase
and consume products as needed and do not substitute across time.9
I focus on a differentiated product market with multiple potential innovators and
imitators, along with insurers and two types of social costs, deadweight loss and entry
cost (cost of innovation or imitation). Using a differentiated product market with
heterogeneous consumers, Klemperer (1990) showed that if consumers all have the
same transportation costs, social cost primarily stems from deadweight loss, making
narrow patents with long lengths optimal. Alternatively, if consumers all have the
same valuation of products, then social cost primarily stems from substitution to
less preferred products, and broad patents with short lengths are optimal. Drawing
innovators that develop differentiated products (Klemperer, 1990; Wright, 1999); and costly inno-
vation or imitation (Gallini, 1992; Wright, 1999).
8 This implies that the total profit earned by the innovator under patent protection is necessary
to induce the given level of innovation. The patentholder’s net present discounted profit V earned
under patent protection is therefore set to be nondecreasing. The significance of this restriction,
which amounts to a form of Ramsey pricing, lies in its implicit assumption that the long-run
innovation flow is not reduced regardless of the policy chosen (Ayres and Klemperer, 1999).
9 If consumers could substitute across time, the roles of patent breadth and length would be more
similar (Klemperer, 1990).
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on these insights, I start by estimating the demand parameters to determine the
substitutability of products to others on the market as well as to the outside good.
The impact of high entry cost was also considered by the literature. Gallini
(1992) considered a market in which imitators pay an entry cost and produce perfect
substitutes that don’t infringe on the innovator’s patent. If patent breadth increases
imitators’ entry cost, then the optimal patent policy was shown to consist of broad
patents with short lengths. Allowing these entry costs to differ among the imitators,
Wright (1999) found that the optimal patents could have narrow breadths and long
lengths if deadweight loss is monotonically decreasing in the number of imitators.
Otherwise, if deadweight loss were nondecreasing in the number of imitators, broad
patents with short lengths would be optimal. To account for the presence of high
entry cost and its potential effect on the modified patent policy, I compare innovators’
discounted profits to their innovation costs. Cases in which the cost exceeds the profit
indicate that the innovators would be better off not entering the market.
2.2.2 Empirical Literature
The empirical literature relevant to the search for optimal patent policy includes
reduced form and structural papers aimed at quantifying the effects of competition
and social welfare in the pharmaceutical industry.10 The first strand of this literature
examined natural experiments stemming from changes to patent policy in the U.S.
and other countries in order to better understand the potential welfare implications
of policy changes. The most notable of the U.S. policy changes is the adoption
of the Hatch-Waxman Act (1984). In streamlining the process and reducing the
costs of generic entry, this law not only ensured that firms with profitable products
would face generic competition after patent expiration, but also reduced the average
10 In this subsection, I provide a brief overview of the relevant empirical literature. For a more
comprehensive review, see Cohen (2010) and Hall and Harhoff (2012).
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time for generic entry after patent expiration from three years to only three weeks
(or less) (CBO, 1998; Schacht and Thomas, 2005; Grabowski and Kyle, 2007). In
some cases, challenges under Paragraph IV of the Hatch-Waxman Act allow generic
firms to enter the market prior to the patent expiration date originally claimed by
the innovator. Branstetter et al. (2011) estimated that paragraph IV challenges led
to a substantial net social gain in the hypertension market over the last decade.
Grabowski and Kyle (2007) examined the decrease in the average amount of time
brand name pharmaceuticals enjoy on the market before generic competition and
found that this shift is even more pronounced in larger markets with blockbuster
drugs.11 Focusing on the international stage, Sakakibara and Branstetter (2001)
examined the impact of the 1988 patent reforms in Japan on the country’s innovative
effort. The authors found little evidence that the uniform expansion of patent scope
led to greater R&D effort by domestic innovators.
The other strand of relevant literature utilized structural frameworks to imple-
ment counterfactual simulations.12 A few papers have estimated the value consumers
place on having follow-on products and/or generics in the market. Using data for the
ADHD drug market, Bokhari and Fournier (2012) found that generic entry led to a
significantly larger welfare increase than entry by follow-on products. Arcidiacono
et al. (2013) found that “me-too” anti-ulcer drugs increase insurer spending by bil-
lions of dollars each year. Next, Chaudhuri et al. (2006) and Dutta (2011) applied a
structural framework to estimate the effect that the Trade-Related Intellectual Prop-
11 One concern discussed in the literature is that this type of reduction in market exclusivity
for patented products has decreased the incentives for future innovators. For more details, see
Grabowski and Kyle (2007), Higgins and Graham (2009), and Panattoni (2011).
12 These papers examined demand through a variety of discrete choice models, including nested-
logit (Stern, 1996b; Mortimer, 1998; Azoulay, 2002; Currie and Park, 2002; Dutta, 2011), principles
of differentiation generalized extreme value (Arcidiacono et al., 2013), random coefficients (mixed)
logit (Cleanthous, 2002; Dickstein, 2011; Yin, 2013) and the almost ideal demand system (Ellison
et al., 1997; Chaudhuri et al., 2006; Bokhari and Fournier, 2012). Several papers also incorpoate
physician/patient learning into their frameworks (Ching, 2010b,c; Dickstein, 2011).
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erty Rights (TRIPS) would have on pharmaceutical industry in India. These papers
found that the new patent rules will lead to substantial loss to consumer welfare and
a relatively small gain to foreign patent holders. However, these results reflect short-
term estimates, couched in the presumption that domestic firms will not engage in
any significant innovative activity. Incorporating consumer learning into the anal-
ysis, Ching (2010c) found that shortening the time between patent expiration and
generic entry leads to a very small welfare gain for consumers. Finally, the closest
work to this chapter was provided by Yin (2013), who estimated the welfare effects of
granting additional periods of exclusivity to original innovators who make incremen-
tal improvements to their own existing products (e.g. new drug formulations, new
indications, or improved efficacy and safety).13 Using the market for antidepressants,
Yin (2013) found that while the value of the incremental innovations in aggregate is
greater than the corresponding costs, some products netted a social loss.
This chapter differs from and contributes to the empirical literature in two ways.
First, I look specifically at the tradeoff between patent breadth and length that has
been the focus of the theoretical literature. In this way, I attempt to limit the impact
of any patent modification on long-run innovation flow. Second, I explicitly consider
different ways of handling how a modified policy would impact the entry of later
drugs.
2.3 Background and Data
In this section, I provide background information relevant to the market structure
and briefly detail the multiple datasets that allow me to implement the counterfactual
simulations. First, I describe the key features of the U.S. Pharmaceutical industry
and explain why it is particularly suitable for an examination of a modified patent
13 The estimation framework used by Yin (2013) is very similar to the one proposed by Dunn
(2012), which found that the quality-adjusted price in the anti-cholesterol drug market decreases
with the introduction of new product innovations.
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policy. I then present information on the antidepressant market, which serves as a
good application for my analysis, given that the data captures the evolution of the
dominant therapeutic drug class.
2.3.1 The U.S. Pharmaceutical Industry
The U.S. pharmaceutical industry differs from most other industries in several im-
portant ways. First, new products in this industry are expensive to develop and
cheap to produce, which implies that the industry is highly dependent on patents
to safeguard innovators’ profits and that it may be more socially efficient to limit
development of all but the most valued innovations. As part of the development
process, innovators must prove that their products are sufficiently safe and effective
in order to enter the market. However, innovators (pioneers and followers) only need
to compare the efficacy of their products to either long-established quality minimums
or placebo control groups. Thus, products following the pioneer can enter the market
with equivalent, or even inferior, quality. As depicted in Figure 2.1, the drug de-
velopment process can take more than a decade, and require thousands of patients,
to complete. DiMasi et al. (2003) estimated that the average out-of-pocket cost of
this process for successfully developed and approved products amounted to several
hundreds of millions of dollars, after accounting for risk of failure. On the other
hand, marginal manufacturing costs per dose tend to be less than one or two dollars,
if not just a few cents. Moreover, given that product development predominantly
occurs after the innovation has been patented, a product generally has between eight
and 14 years of patent protection remaining once it reaches the market (this period
is commonly referred to as the effective patent life).
Second, each pharmaceutical product innovation is generally distinct in molecular
structure from other product innovations, even though they may be used for the
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exact same purpose and be very similar in quality.14 Under the current policy, each
pharmaceutical patent protects the active component of the molecule and allows the
innovator to generalize on the weak or inert components that may be combined to it.
While technically a patent can be further narrowed in scope to all complete molecules,
this would amount to a substantial burden on innovators, since the innovation tends
to be fully embodied in the active component and the rest represents little more
than filler. In this way, pharmaceutical patents represent as narrow a scope for
patent protection as is feasible (henceforth, I refer to this measure of patent breadth
as the molecule level).
The next key feature of this industry is that pharmaceutical product innovations
are patented before their value is known, normally at the beginning of the develop-
ment process (Mossinghoff, 1999; Grabowski, 2002). Usually, by the end of Phase
II, innovators have gained their first significant evidence of efficacy and safety (Di-
Masi et al., 1991; Mossinghoff, 1999). This means that innovators might wait as long
as seven or eight years after applying for the patent before they know the value of
their product, and another four to five years before they can enter the market (see
Figure 2.1). The temporal disconnect between these events means that a “me-too”
innovation will be patented before it is known to be a “me-too”. For this reason,
the conventional framework of patent policy needs to be adapted to focus on which
products may enter the market, rather than strictly specifying the products that are
owned by a given innovator. The need to exclude the ownership requirement stems
from the molecular differences between the groundbreaking and “me-too” innova-
tions, which are described above. In practice, greater patent breadth on high-value
innovations would mean that innovators of “me-too” products would still retain their
patents, but be restricted from entering the market.
14 Exceptions to this include the type of incremental improvements innovators make to their own
products in order to get additional periods of exclusivity. This paper focuses on small molecule
(non-biologic) patents that identify the chemical structure and activity of a new compound.
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A fourth key feature is that products belong to therapeutic classes, which are
categorized according to the mechanism or chemistry that the products target in the
body and, typically, more than one therapeutic class is used for a specified treat-
ment. In this way, there is a limit to the degree to which two products in the same
therapeutic class can be differentiated. Given that this classification is independent
of any decisions made by the firms, it provides a clear level to which breadth could be
expanded from the current molecule level. The only other potentially feasible level
that breadth could take in this context would be to encompass the full antidepressant
market, but still allow prior market entrants to remain.15
Next, entry in this industry by generic drug competitors once the patent has
expired provides substantial cost savings to consumers. Indeed, generic entry has
been observed to reduce a molecule’s average price by as much as 80% within 18
months after expiration (Jena et al., 2009). Competitive pressure stems not only
from the number of generic entrants, but also from state laws that permit or require
pharmacists to dispense an available generic version, unless expressly prohibited by
the perscribing physician. Therefore, as long as developers of high-value drugs have
sufficient incentive to innovate, enabling earlier generic entry on these drugs to occur
will allow consumers to enjoy these gains that much sooner.
The final key feature of the pharmaceutical industry is that most consumers
generally pay only a small fraction of a product’s full price, called the copayment
or copay, while their prescription insurer pays the rest. For this benefit, consumers
(or their employers) regularly pay a premium to their insurer. With the market
power that results from covering many consumers, insurers are then able to negotiate
15 While I ignore the possibility that a drug may be used for multiple completely different markets
(treatments), it is a simple matter to focus the entry restriction to only a specified market and still
allow access in other markets. For example, the popular hair treatment Rogaine (minoxidil) is also
used to treat high blood pressure (under the trade name Loniten). Even if it had temporarily been
blocked as a high blood pressure medication, as the first hair growth drug approved by the FDA,
it would be free to enter this second market.
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reduced prices with the drug manufacturers, often in the form of a rebate. I discuss
the available data below.
2.3.2 Data
To analyze this market, I combine several data sets. I acquired the first from SDI
Health (hereafter, “SDI”).16 This data contains monthly, national-level revenue and
quantities for prescription drug sales by retail vendors, over the period 1991 to 2010.
Observations are broken down by individual drug, identified by either its brand name
or as a generic, its formulation (i.e. capsule, tablet, etc.), the dose size, and the
manufacturer that produced it. While this data takes into account discounts, it does
not include rebates.17 For this reason, retail prices may not represent the effective
product prices, but they are the best data available to the public.18 Additionally,
the SDI data does not include sales through hospitals or prescriptions provided to
consumers directly from third party institutions, such as psychiatric institutions and
the military.19
A drawback of the SDI data is that it reflects information reported by retailers,
rather than by manufacturers. Hence, the data does not consistently capture changes
in ownership among manufacturers and also includes sales attributed to firms that
16 Shortly after this data was purchased, SDI Health was acquired by IMS Health.
17 As previously discussed, rebates are direct payments from drug manufacturers to health care
providers and they represent another dimension in which patented molecules can compete for sales.
Unlike discounts, which are observed by the entire market, rebates are generally kept confidential
between the two entities in the agreement.
18 While rebate data are not publicly available, some inference can be made on their bounds and
volatility. Under the Medicaid Drug Rebate Program, branded drug manufacturers must give the
U.S. government either 15.1% off of their average price or their best rebated price, if it is lower.
Hence, it is likely that manufacturers only rarely exceeded this threshold prior to generic entry
on the drug (Arcidiacono et al., 2013). Additionally, it is likely that rebate agreements between
manufacturers and insurers are generally negotiated on an annual or semiannual basis, which limits
their impact on volatility in the national average price per drug.
19 Expenditures through third party payers, including the military, ranged between 3% and 5% of
total national expenditures between 1991 and 2010. Additional information can be found through
the Centers for Medicare & Medicaid Services website: http://www.cms.gov/Research-Statistics-
Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/index.html.
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merely package or distribute the pharmaceuticals, rather than the true manufactur-
ers. To remedy the issue with changes in ownership, I conducted an extensive search
through public filings and company websites to identify mergers and acquisitions
among the relevant firms. To address the second issue, I use the FDA’s National
Drug Code Directory (NDC) database to determine firm affiliations according to
two key identifiers, NDC Number and Application Number. Given the sparsity of
the historical data available on the FDA’s website, I obtained a more comprehensive
dataset through a Freedom of Information Act (FOIA) request.20
I acquired the second data set that I use from Encuity, Inc. This data includes
monthly, national-level advertising to physicians, nurse practitioners, and physician
assistants (also known as “detailing”). It is generally understood that marketing
strategies for branded drugs include a great deal of detailing expenditures, while
generic manufacturers rarely engage in this practice. It should be noted that generics
are not necessarily considered perfect substitutes by consumers for many reasons,
including brand loyalty and preferences for formulation, flavor, and even color.21
However, their efficacy and side effect profiles should be very similar, if not identical,
to their branded counterparts, for any given molecule. Due to some data limitations,
I do not include advertising that directly target patients. However, the effect if this
is likely mitigated by the fact that patients and doctors generally make the product
decisions together and I include advertising to physicians.
Finally, I use the MarketScan Commercial Claims and Encounters (CCAE) Database,
obtained through the National Bureau of Economic Research, which consists of a
nation-wide sample of healthcare insurance claims provided by large employers and
20 Additional information on the historical data available through the FDA’s website can be found
at www.fda.gov/Drugs/InformationOnDrugs/ucm142438.htm.
21 Ching (2010c) and Ching (2010b) provide some support that consumers preceive this difference
between a brand product and its generic versions. These papers argue that consumers are ini-
tially uncertain about the quality of generics and that the rate of generic diffusion is explained by
consumers learning from others’ use.
19
health plans. This data set is comprised of patient-level prescription drug purchases
between 1996 and 2009. It includes patient copay expenditures per prescription
as well as some corresponding insurance plan information. However, the consumer
premiums paid to insurers are not available.
2.3.3 The Antidepressant Market
Major depression or lower-level chronic depression affects 9.1% of adults in the United
States.22 However, according to The National Ambulatory Medical Care Survey, the
number of people receiving treatment for depression tripled between 1987 and 1997.
In studying this trend, Olfson et al. (2002) noted that this substantial increase “co-
incided with the advent of better-tolerated antidepressants, increased penetration of
managed care, and the development of rapid and efficient procedures for diagnosing
depression in clinical practice.” These concurrent events imply that the new drugs to
the market were of higher quality, and consumer costs were reduced by the increase
in insurance coverage and the improved diagnostics. Figure 2.2 shows that drug sales
in this market increased substantially over time. Antidepressants are generally cate-
gorized into four main therapeutic classes. Each class targets a different mechanism
in the body in order to elicit the desired effect.
The first two of these classes are generally considered by the medical literature to
be first-generation antidepressants. In the early 1950’s, monoamine oxidase inhibitors
(MAOIs) were found to reduce the symptoms of depression and were introduced as a
treatment. However, MAOIs were temporarily taken off the U.S. market when it was
discovered that under specific conditions, the drug could cause death. The promise
22 See the Centers for Disease Control and Prevention (CDC) revised estimates for more details
(www.cdc.gov/features/dsdepression). Prevalence rates identified in other papers vary. Dickstein
(2011) cites a prevalence of 6.5% for adults affected by major depression, Berndt et al. (1996) note
survey evidence that indicates a 9% prevalence rate for major and lower-level chronic depression
among the employed labor force, Greenberg et al. (2003) use the Epidemiologic Catchment Area
survey to support a 10.1% rate, and Kessler et al. (2005) find a rate of 8.2% across all adults.
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of MAOIs led to continued research on treatments for mental illness. By the 1970’s,
tetracyclics (TCAs) had been shown to increase the brain’s supply of norepinephrine
and serotonin and were introduced as the second therapeutic class. While not as
likely to cause death, TCAs offered little added benefit in efficacy and contributed
to a host of other side effects that range from mild to severe.
The second-generation antidepressants include the last two classes. The most
prominent antidepressant class consists of selective serotonin reuptake inhibitors (SS-
RIs), which elevate only serotonin in the brain. While SSRIs did not offer significant
benefit in efficacy over MAOIs or TCAs, their side effects were not nearly as frequent
or severe. Little more is known about the true way that these chemicals influence
depression. The last class is also the least well understood. This class is often re-
ferred to as Other Antidepressants or as New Generation Antidepressants (NGAs).
NGAs appear to allow for increased levels of norepinephrine and dopamine in the
brain. Nearly all of the products sold under patent during the date range of the SDI
data belong to either the NGAs or SSRIs.
Figures 2.2 and 4.1 provide monthly totals of daily-dose sales by therapeutic
class and molecule, respectively. While the TCAs are the dominant drug class at the
start of my time period, they experienced a steady decline thereafter. Conversely,
the NGAs drew a sizable share of the market during the same time period with
the introduction of several new molecules. However, the SSRIs clearly became the
dominant class of antidepressants. MAOI sales are included in Figure 2.2, but are
too small to see. Figure 4.1 illustrates how quickly sales for branded molecules can
be overtaken by their generic counterparts after patent expiration. Prozac’s patent
expired in mid-2001 and within a few months, most of fluoxetine sales were made by
generics. Similar switching can be observed for Zoloft and Celexa.
The SSRIs began in 1988 with the market introduction of Prozac, which im-
mediately became the dominant product in the market with annual sales of over $1
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billion. Figure 2.4 shows weighted average prices for SSRI products, presented at the
daily-dose level in 2010 dollars. Following on Prozac’s success, Zoloft was released in
early 1992 and competed at a price that trended downward, falling below Prozac’s
price by the end of 1995. Then Paxil, in the beginning of 1993, and Celexa, in the
second half of 1998, were each released with prices significantly higher than either
Zoloft or Prozac. The remaining SSRIs entered the market after Prozac’s patent
expiration. It is important to note that generic prices on each of the first four SS-
RIs (denoted by the dashed lines) begin close to their brand counterparts and then
quickly drop thereafter. Specifically, average daily-dose price for generic variations
of Prozac (fluoxetine) starts at a high of $3.07 and falls to $0.76 within 18 months.
As previously mentioned, advertising is an important component of competition
in the pharmaceutical industry. Firms spent an average of $8.5 million per month
to advertise Prozac, Zoloft, and Paxil to physicians during the molecules’ patent
protected period. However, there were small increases in advertising for Zoloft and
Paxil around the time of Prozac’s patent expiration. This suggests that firms that
correspond to these drugs were attempting to limit consumer switching from their
respective products to generic variations of fluoxetine. Advertising expenditure was
nearly double the average amount for Lexapro. For each brand name, advertising
quickly tapered off after its patent expired. Interestingly, this tapering off of brand
advertising provides a countervailing effect that balances with the lower generic pric-
ing. This likely explains why total quantity sales on many molecules remain stable
in the years around a brand’s patent expiration. Generic manufacturing firms might
advertise only if they are the first to enter on a given molecule and then stop once
other generics enter the market.
The comparison between the prescription-level retail prices and the copays paid
by patients is presented in Table 4.1 for a selected sample of the top sellling NGA
and SSRI drugs. The average retail price for a prescription of brand drugs tends to
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be over $100, while an insured patient’s expense ranges between $15 and $30. This
means that insurers pay the vast majority of the cost of these prescription drugs.
The retail prices of generics tend to be about half the price of the branded drugs, if
not less. For generics, insured patients pay around $10. Also included in the table
are the dates that the molecules first launched onto the market and their first patent
expiration dates.23 Next, are the number of generic producers that compete under
a given molecule. Note that while generic manufacturers do provide a great deal
of price competition, these products may still be differentiated by formulation and
manufacturer.
The antidepressant market provides a particularly useful example in examining
modified patent policy for a few reasons. First, the market consists almost entirely of
prescription drugs, which implies that sales are more likely to be captured in the data.
Second, sales in the antidepressant market over the period 1991 to 2010 were domi-
nated by SSRI manufacturers, which mostly consisted of large pharmaceutical firms
that relied on patent protection to prohibit generic competition. Finally, the data
captures the competitive evolution of the dominant therapeutic drug class. While
the entry of the pioneer molecule in the SSRI class is not observed, the data does
capture the entry of all subsequent products. I examine the impact of broadening
Prozac’s patent’s breadth while simultaneously shortening its patent length in order
to reduce incentives for the some of the subsequent SSRI entrants, which I assume
to be “me-too” products. Once these profits are earned, the modified patent would
expire and allow both generic competitors and the available “me-too” products to
enter.
23 As previously mentioned, innovators occasionally patent new formulations of their products in
an effort to extend their market exclusivity.
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2.4 The Model
In this section, I present a static model of differentiated-product demand and sup-
ply which will be used to determine the shape of the demand curve and recover the
implied marginal costs. Building off of Berry (1994) and Cardell (1997), I estimate
demand using a three-level nested-logit model, which adequately provides the flexi-
bility of substitution patterns that will be applied to the counterfactual simulations.
I then apply these estimates to a supply model and equilibrium conditions similar to
those proposed in Nevo (2000a). This approach allows me to implement the modified
policies by simply removing products from the market and then reoptimizing price
to equilibrium.
2.4.1 Product Price and Consumer Copay
As presented in the previous section, the copay paid by insured consumers for product
j at time t, given by cjt, tends to be substantially lower than the price the set
by manufacturers, pjt. Insurers generally assign drugs to three copay tiers, based
on their relative prices. High priced brand drugs tend to be assigned to the top
tier (non-formulary), which may have a copay around $50 per prescription, while
more moderately priced brands are assigned in the second tier (formulary) may have
a copay of $30 per prescription. The final tier is for generic drugs, which tend
to have a copay of $10 per prescription (see Table 4.1). Since these assignment
decisions are likely independent of any specific drug or class of drugs, I treat them as
given. Moreover, I assume that insurers play a passive role, limited to their payment
expenditures on consumer purchases.
I model the relationship between copay and price as a power function with a
power value less than one (Arcidiacono et al., 2013).24 In particular, I assume the
24 The power function dampens high prices, which matches the trends observed in the data.
24
form
cjt  p
φ
jt  e
γ0 Xcjtγ1   νjt, (2.1)
where Xcjt are observed product characteristics, νjt is an error term, and tφ, γ0, γ1u
is the set of parameters to be estimated.
2.4.2 The Demand Side
Suppose consumers choose from an assortment of products which belong to two
levels of nests (or groups). Let g index the nests in the upper level and mg index the
groups in the lower level, the subnest. While consumers consider all of the products
in their choice set, products within a nest (or subnest) are more similar in value than
those across nests (or subnests). Within this three-level nested logit framework, a
consumer is assumed to first choose a nest g (a therapeutic class), then a subnest
m (a molecule) from those available in g, and finally a product j from those within
subnest m.25
The indirect utility that consumer i gets from product j at time t is given by
uijt  δjt   ψijt (2.2)
where δjt  Xjtβ   αcjt   γlnpamgtq   ξjt (2.3)
and ψijt  ζig   p1  σgqζimg   p1  σgqp1  σmgqεijt. (2.4)
The first term in equation (2.2) is the mean utility level of product j, which is a
function of observed product characteristics (Xjt) and those characteristics which
are observed by consumers but not by the econometrician (ξjt). The mean utility
also includes the consumer’s copay, cjt, and the natural log of the advertising, amgt,
25 In order to avoid the complexity of decision-making and consumption involved in this setting,
I assume that the “consumer” includes both the prescribing doctor and the patient who uses
the medication, and that patients are fully compliant in using all of the prescribed medication
they purchase. Dickstein (2011) employed a dynamic learning model that relaxes both of these
assumptions. Additionally, I assume that a “producer” includes the drug manufacturer as well as
the pharmacies that sell its product to consumers. Both of these assumptions are common in the
literature.
25
for product j.26 Since firms may offer multiple products within the same subnest m,
I assume that a firm simultaneously advertises this collection of products and index
advertising accordingly.
The other term in equation (2.2) is the heteroskadastic error, which captures the
effects of the random taste parameters and reflects the form of the nesting structure.
For consumer i, ζig and ζimg capture the unobserved variation common to all products
indexed by g and m, respectively. Within the bounds of [0,1), σg and σmg measure the
importance of the structure that defines each nest (subnest) as being distinct from
the rest of the sample. As σ approaches one, the products in the same nest (subnest)
can be considered stronger substitutes, than products across nests (subnests). If σ
is zero, preferences for the products within the nest (subnest) are not correlated in
any way distinct from the rest of the products and the model simplifies to either the
nested logit (if σ for only one of the levels is zero) or the standard logit model (if
both).
Finally, εijt represents the distribution of consumer preferences around the mean
valuation ξjt and is assumed to be an identically and independently distributed (i.i.d)
extreme value. Cardell (1997) shows that ζ1 and ζ2 have unique distributions, such
that if ε is an extreme value random variable, then so is ζ1   p1  σ1qζ2   p1 
σ1qp1  σ2qε. Berry (1994) and Nevo (2000b) note that an important implication
of the i.i.d assumption for εijt across customers and choices is that products in the
same nest are solely differentiated by the mean utility levels, δjt. Hence, market
shares and elasticities are solely determined by δjt. However, when some products
are more similar than others, this dependence on just δjt for consumer choices will
result in estimated product substitution patterns that do not match the true patterns.
26 Allowing advertising to enter the utility function in this way captures the persuasive role it
has on consumer choices. However, given the possibility that consumers may be uncertain about
the quality of new drugs, advertising might also play an important informative role (Ching and
Ishihara, 2010, 2012). In Section 2.5.1, I discuss the use of fixed effects to incorporate consumer
learning into the estimation.
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The advantage of the nested-logit model over the standard logit model is to lessen
this restriction on substitution patterns by grouping products known to be more
comparable into nests. Despite its reliance on the a priori assumption on how the
market is segmented into nests, this framework provides sufficient flexibility on the
substitution patterns for my needs.27 Another feature of logit models is the S-shaped
nature it imposes on demand. Whether firms price in the convex or concave regions
is determined by the parameter estimates and costs.
Following the three-level nested logit analog of Berry (1994) and defining η 
r1  p1  σgqp1  σmgqs P r0, 1q, the demand equation can be restated as
lnpsjtq  lnps0tq  Xjtβ   αcjt   γ lnpamgtq   σg lnpsmgtq   η lnpsjt{mgq   ξjt. (2.5)
The first term on the left-hand side is the log of the market share of product j at time
t, while the second term is the log of the share of the outside good in the same period.
Finally, at time t, sjt{mg is product j’s share of sales by all products in subnest m
and smgt is subnest m’s share of sales by all products in nest g. The derivation of
this form of the demand equation is provided in Appendix A.
2.4.3 The Supply Side
Suppose there are F firms, each of which produces some subset, Jft, of the j 
1, ..., Jt different products available at time t  1, . . . , T . The profit of firm f at time
t is
Πft 
¸
mPJft
¸
jPm
rppjt mcjtqMtsjpptqs  amt  Cft (2.6)
where sjpptq is the market share of product j and is a function of the prices of all
products at time t. Note that I hold advertising fixed and do not attempt to solve
for new advertising trajectories when performing counterfactuals. The market size
27 The market I focus on experienced a great deal of product entry during my sample period. Given
that the Almost Ideal Demand System (AIDS) approach does not have a good way of dealing with
a varying number of products, I chose not to use it (Chaudhuri et al., 2006).
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at time t is denoted by Mt, mcjt is the marginal cost of production, and Cft is the
fixed cost of production.
In line with the literature, I assume that there’s a unique Bertrand-Nash pricing
equilibrium, with prices that satisfy these first-order conditions.28 A key feature of
this assumption is that it enables me to measure the impact of alternative policies on
social welfare. For firm f at time t, let r index the individual products in Jft. The
price, pjt, and the marginal cost, xmcjt, for product j must then satisfy the following
first-order condition (FOC):
sjpptq  
¸
rPJft
pprt  xmcrtqBsrpptq
Bpjt
 0. (2.7)
The Jft equations in (3.13) can be used to calculate the price-cost margins for each
product. I define
Ωprejr pptq 
"
Bsrpptq{Bpjt if Df : r, j P Jft
0 otherwise
(2.8)
and substitute it into the vector form of the FOC to get
spptq  Ω
prepptqppt  xmctq  0.
This equation can then be rearranged and used to solve for the markups and the
implied marginal costs
pt  xmct  Ωprepptq1spptq ñ xmct  pt  Ωprepptq1spptq. (2.9)
28 The validity of this assumption is supported by conversations with pharmaceutical industry
experts and ample evidence in the relevant literature, which indicate that firms compete by setting
prices. In most markets, products are differentiated and firms are not capacity constrained. Addi-
tionally, Nevo (2001) found that the Bertrand-Nash equilibrium leads to more accurate predicted
margins than other behavioral models. The assumption of a static game does ignore potentially
important dynamics that could stem from consumer switching costs, brand loyalty, and advertising.
For example, Lu and Comanor (1998) examined pricing strategies by new pharmaceutical entrants
and found that high-value drugs were introduced at prices two or three times those of existing
drugs, while very similar value drugs entered at similar prices.
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Assuming marginal costs are not observed, equation (3.16) allows these values to
be calculated using the demand system estimates.29 This equation can also be used
to simulate the equilibrium prices under the modified policy by returning to the
previous Bertrand-Nash equilibrium assumption.
2.5 The Estimation
I estimate the parameters of the model presented in the previous section using the
data discussed in Section III. I consider each therapeutic class to be a different top-
level nest and each molecule to be a bottom-level nest. Thus, the consumer first
chooses one of these classes or the outside good, then a molecule from that nest, and
finally, a specific product of the molecule.
Observed characteristics include whether the product is a brand or generic, the
form of the drug, who produces it, the months in which it was purchased, and how
long the molecule has been on the market.
2.5.1 Market Size and the Outside Good
To form my sample, I take the following steps. First, I assign molecules in the SDI
database to their corresponding therapeutic classes according to the Anatomical
Therapeutic Chemical (ATC) Classification System.30 Next, I follow the established
path of defining daily dose as a common basis of comparison to allow for the estima-
tion of substitutability between products (Stern, 1996b; Berndt et al., 1996; Currie
and Park, 2002). I use the Physicians’ Desk Reference for various years to establish
29 However, it is important to note that marginal cost estimates rely on the use of consistent
demand system estimates. Inconsistent estimates may result in implied marginal costs that appear
to jump erratically over time. Additionally, non-negative marginal cost estimates rely on the model
correctly capturing firms’ profit maximizing behavior.
30 Established by the World Health Organization Collaborating Centre for Drug Statistics Method-
ology in 1982, the ATC classifications provide a clear system by which innovating firms can deter-
mine to which drug class their innovation corresponds. Moreover, since firms generally sell their
pharmaceutical drugs to multiple countries, this international classification system is appropriate.
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each molecule’s daily maintenance dose levels and divide dose sizes by these corre-
sponding values. These results are then multiplied by the monthly unit sales and
divided by the number of days in that month. Third, I calculate the antidepressant
market size by multiplying the prevalence rate of depression by both the U.S. Cen-
sus Bureau’s monthly estimates for the civilian population and by the proportion of
people that are at least 18 years of age.31 Fourth, prices are inflated to December
2010 dollars using the Consumer Price Index from the Bureau of Labor Statistics.32
Finally, for ease of computation, I aggregate the data in two ways. First, I aggregate
doses for each brand, manufacturer, and form in a given month. While resulting
in a substantial reduction, this step still leaves over 700 brand-manufacturer-form
combinations per month. As discussed in Section 2.3.2, I then combine firms that
are affiliated through production chains or mergers and end up with 364 products.
This last step is particularly relevant to generic drug manufacturers, many of which
had merged with or acquired other generic manufacturers. However, the data still
includes multiple distinct generic products for each molecule not under patent.
To estimate the relationship between copay and price, I use the MarketScan
CCAE Database merged by drug and month with prices from the SDI database.
Copay values are taken from the insurer listings that correspond to each patient
transaction. I exclude observations in which the corresponding insurer plan requires
patients to pay anything other than a copay.33 The parameters in equation (2.1)
are estimated on patients’ transaction-level data with prescription-level prices, and
weighted by the number of enrollees in each plan. These estimates are then converted
to the daily-dose level and incorporated into the demand estimation.
31 Both the SDI database and the U.S. Census Bureau estimates exclude people who are in the
military or are in institutional facilities. (http://www.census.gov/popest/).
32 The Consumer Price Index can be found at http://www.bls.gov/cpi/.
33 In the MarketScan CCAE database, some patients are observed to pay other costs, such as
co-insurance and a deductible. However, a majority of the observed plans require patients to only
pay a copay.
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In estimating the demand, I account for both time-varying and time-invariant
effects. A number of time-varying product characteristics, (cjt,Xjt,amt), enter the
consumer’s utility. Among the Xjt characteristics, I first include patent expiration
dummies for each molecule to capture any changes in how a product is perceived by
consumers. Next, I include time dummies, alone and interacted with a therapeutic
class identifier, to capture news that enters the market and affects consumer per-
ceptions. Additionally, I incorporate months-on-market dummies for the first twelve
months after a molecule enters the market in order to isolate trends in product avail-
ability or consumer awareness and/or learning.34 These dummies are allowed to
vary by therapeutic class. Finally, I include copay at the product level and log ad-
vertising at the manufacturer-molecule-month level. This paper treats advertising as
exogenous. Pharmaceutical firms typically lay out their advertising schedules far in
advance and these expenditures do not appear sensitive to monthly demand shocks
that are commonly absorbed into the error term. Furthermore, I do not attempt to
solve for new advertising levels in the counterfactuals, but I do exclude advertising
for products that have been removed from the market. The time-invariant character-
istics are captured by molecule-level and manufacturer-form-level fixed effects. The
distinction is necessary due to the nesting structure of the model.
Following Nevo (2003), I make two important assumptions relevant to the in-
terpretation of the counterfactual results. First, I assume that the quality of the
outside option (possibly, therapy or nothing) does not decrease over time.35 Second,
I assume that any changes in consumers’ perceived value of a product’s unobserved
characteristics primarily stem from changes of those characteristics that happen over
time. Hence, ξjt is allowed to vary over time in the welfare calculation.
34 For robustness, I included longer periods of time and found no meaningful variation.
35 This assumption was included after conversations with several industry experts and medical
practitioners.
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2.5.2 Instruments
Following Stern (1996a,b), I instrument for product prices and the potential endo-
geneity of the within-nest shares using supply-side factors. These instruments are
intended to be unrelated to the unobserved heterogeneity (possibly quality), but
are systematically correlated with pricing decisions and the determinants that affect
within-group share. The first set of instruments are those based on the amount of
competition within a nest. For a given product, I count the total number of other
products in the nest that are generics, the percentage of those other products that
are generics, and the number of other firms that sell products in the nest.36 These
three simple measures capture the degree of competition a given product faces, but
should not be related to unobserved quality. Also, I can use the total sum of time
since entry of other products in the nest as an instrument. The FDA imposes strict
regulations on the drugs sold on market and all changes to an approved product must
also be approved. Hence, controlling for a product’s own time on market, the aggre-
gate time since entry of all other products will not be related to a given product’s
unobserved quality.
As noted by Stern (1996a,b), multi-product market power is also likely to influ-
ence prices, but not unobserved quality. To that end, the second set of instruments
I employ are the numbers of other products sold by a given product firm in each
nest. Since firms are assumed to maximize profits over their entire product portfolio,
changes to the portfolio will affect the prices it sets, but not the unobserved quality
of a given product.
36 One concern raised by Ellison et al. (1997) to the use of the number of firms as an instrument
is that firms could be entering or exiting a market in response to changing demand characteristics.
While this is a valid concern, I do not find a great deal of this type of movement by firms in the
data. I observe a great deal of entry, but not as much exiting. Further, it is rare to see a product
enter the market, leave, and then re-enter.
32
2.6 Estimation Results
In this section, I review the estimates of the model and compare them to findings
in other papers. I start with the copay-price relationship defined in equation (2.1),
which is estimated by nonlinear least squares regression. As expected, Table 2.2
shows a positive relationship between copay and price. More specifically, a one
percent increase in the price of product j results in roughly a 0.42% increase in the
copay for that product.
The copay regression results allow me to estimate demand based on the costs that
patients observe. Table 2.3 provides the key demand-side parameter estimates. The
nest parameters imply that the therapeutic class designation is meaningful. That
is, products in the same therapeutic class are considered better substitutes and so,
consumers are less likely to switch to other product classes. Given that a molecule
belongs to only one therapeutic class, the second parameter will be larger by con-
struction. However, there is still some meaningful distinction between molecules.37
The estimated parameters on the fixed effects are also meaningful. The months-on-
market parameters show that the SSRI class were slow to gain traction in the first
couple of months, but resembled the other drugs on market soon after.
Own-price and cross-price elasticities provide additional insight into how a change
to patent policy will affect a market.38 Using the demand estimates, I calculate the
own-price elasticities to range between -1.6 and -3.2 for the two dominant therapeutic
classes, shown in Table 2.4. The average cross-molecule elasticities for the SSRI class,
which are presented in the last four rows of the last column, are quite large. These
imply that blocking one of these products from the market will have a substantial
positive impact on the market shares of the other SSRI products. Alternatively,
37 Omitting the class-level nests and estimating demand as a simple nested logit with molecule-level
nests, yields an estimate of similar magnitude to the coefficient for lnpsjt{mg q.
38 I provide the derivation of these elasticities in Appendix A.
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the cross-class price elasticities in the first four rows of the last column are relatively
small. This implies that if an SSRI product is blocked from the market, consumers are
not very likely to switch to an NGA product. Additionally, any product blocked from
the NGA class would have an even lower impact on the SSRI products. These results
indicate that substitutability within a given drug class is quite high, which suggests
that extending patent breadth from the molecule level to the therapeutic class may
be welfare improving. Beyond that, the products are sufficiently differentiated that
extending breadth to the full market would most likely have a negative impact on
both producers and consumers by comparison.
A few other papers have examined the antidepressant market with mixed results.
Mortimer (1998) used three years of data from the early 1990’s to estimate own-price
elasticities for branded drugs in this market range between -1.9 and -1.1, but with
small cross-price elasticities. Alternatively, Cleanthous (2002) used annual data and
found own-price elasticities between -0.54 and -0.02, and similiarly small cross-price
effects. Both Mortimer (1998) and Cleanthous (2002) rely on average retail prices
rather than copays in their demand estimation which may explain why they found
consumers to be less price sensitive. Finally, Dickstein (2011) employed a dynamic
learning model on patient-level claims data and reported own-price elasticities that
range between -0.9 to -0.24.
2.7 Modified Policies
This section provides a framework that measures the welfare implications of modify-
ing patent breadth and length, which is then applied to the pharmaceutical industry.
As suggested by the theory, I utilize my estimates of consumers’ substitution behavior
as well as features of the market to inform my analysis.
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2.7.1 Overview
An empirical assessment of the trade-offs between patent breadth and length is mo-
tivated by two key factors. The first is that this assessment would better inform
the theory and provide additional insight to policymakers. While some of the prior
applied literature has attempted to provide insights through indirect analysis, this
paper is the first to directly examine this trade-off. The other key factor is the debate
on the value of “me-too” drugs. This paper provides an approach that allows for a
more reasonable comparison of the value of these products to the potential value of
ealier generic entry on high-quality drugs. The approach is also extended to consider
the incentives of “me-too” innovators to provide more accurate welfare calculation.
The abstract search for an optimal patent policy is limited to what is feasible for
a given market. As previously mentioned, any analysis that searches for an optimal
patent policy requires that the measure of patent breadth be defined in such a way
that is known to the market and independent of any decisions made by the firms. For
the pharmaceutical industry, there are three such feasible levels for breadth. The
narrowest is the molecule level, which is the breadth specified under the existing
policy. The other two are the therapeutic class level and the entire market. I expand
breadth to the therapeutic class and then scale the patent length in order to make
the high-value innovator indifferent between the two policies.39
For my policy experiments, I model patent breadth on the high-value innovation
as the degree to which it can restrict “me-too” products from entering the market.40
Moreover, I allow those “me-too” innovators that are restricted from the market to
keep their patents under the modified policy.41 The implication of this is that once
39 This follows the conceptual framework in much of the prior literature.
40 As discussed in Section 2.3.1, the temporal disconnect between when an innovation is patented
and when its value is known implies that the conventional framework of patent policy is not well
suited for examining alternative levels of patent breadth and length.
41 This paper focuses on only one market. In footnote 15, I discuss how the framework can be
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the patent on the high-value product expires, the “me-too” products can then enter
the market.
For the purpose of exposition, Figure 2.5 depicts the profit over time for both a
high-value innovation, m0, and a subsequent “me-too” innovation, m1. Upon its en-
try, m1 negatively impacts the profit of m0. I propose a policy modification whereby
m0’s patent breadth is increased so as to exclude m1 from the market, while simul-
taneously limiting its patent life to ensure at least the same net present discounted
profit earned under patent protection, V f . Figure 2.6 portrays this balance with
the shaded regions, which are equivalent in present discounted value. In practice,
m0’s net present discounted profit under patent protection may be greater than V
f if
time is treated as a discrete measure. As previously mentioned, the market exclusion
restriction on m1 expires with m0’s patent.
I focus my analysis on the market for antidepressants, in which Prozac was the
first SSRI and was clearly a high-value innovation. Given that there is no formal
definition or explicit quality threshholds that distinguish high-value and “me-too”
innovations, I assume that the four SSRI products that enter the market after Prozac
are “me-too”s. Note that this assumption is independent of how consumers may view
these products.42 I extend Prozac’s patent breadth to the therapeutic class level and
temporarily exclude these “me-too” innovations. This restriction only applies to
subsequent entrants in the SSRI class and therefore, innovations in other classes
would not be directly affected.
Below, I present two counterfactuals. The first assumes that all “me-too” innova-
tions that entered under the original policy also enter under the modified policy, once
Prozac’s shortened patent length expires. For the second counterfactual, I provide a
adapted to allow for products that compete in multiple markets.
42 Ongoing work relaxes this assumption and allows for the consideration that these subsequent
products may themselves be high-value innovations.
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framework which allows “me-too” innovators to anticipate the impact of the modified
policy and re-optimize their entry decision before entering Phase III clinical trials.
Innovators that choose to forgo additional drug development and eventual market
entry would save the associated investment costs.
2.7.2 Counterfactual Pricing
Under the counterfactuals, equilibrium prices are determined for the set of products
on the market in each period. To do so, the implied marginal costs under the current
policy are assumed to remain the same under the counterfactual policy. I define the
matrix Ωpost according to equation (3.14) under the modified policy. The predicted
equilibrium price, pt , under the modified policy solves
pt  ymct   Ωpostppt q1sppt q (2.10)
where ymct is the implied value calculated from equation (3.16). This equation en-
tails a couple of nontrivial assumptions in addition to the Bertrand-Nash equilibrium.
First, I assume that the cost structure between the two policies remains the same.
Second, the matricies Ωpre and Ωpost are assumed to rely on the same demand esti-
mates. Hence, the alternate market structure and resulting price differences for the
remaining products are assumed to capture all the differences between the two sys-
tems. This implies that firms do not change their strategies in any other dimensions
that may affect demand.43
2.7.3 Exogenous Entry
Social Welfare under Exogenous Entry
The net discounted social welfare impact of the modified policy is the sum of the
discounted effects on consumers (CV ), insurers (Πins), and producers (Πdiff ).44 This
43 As previously discussed, advertising is held fixed.
44 Producers include both innovators and manufacturers.
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is given by
SC  CV   Πins   Πdiff . (2.11)
I assume that consumers and insurers have an annual discount rate of 5% while the
producers’ discount rate is 11%, which accounts for the innovator’s risk of product
failure during the product development process (DiMasi et al., 2003). The use of
this higher producer discount rate means that, for a given amount of patent breadth,
the innovator of the groundbreaking drug will require relatively less patent length in
order to realize V f . Under exogenous entry, consumers benefit from this shortened
patent length due to the expedited entry of the generics on Prozac’s molecule.45 The
implications for the “me-too” innovators is less clear. While they are able to enter
the market sooner under the higher discount rate, they also place greater value on
the time they are restricted from the market. However, I find that the final results
are not qualitatively different when I use a 5% discount rate for producers.
As previously noted, prescription drug costs comprise only a small fraction of
household income. Thus, I use compensating variation to calculate the impact that
switching to the modified patent policy will have on consumers. Interestingly, this
impact can be fully captured by the difference in log shares of the outside good under
the two policies, magnified by the size of the market and translated into dollars by
the disutility of price (copay) (Arcidiacono and Miller, 2011). For all consumers at
time t, this is given by
CVt  
Mt
α

ln
 
sante0t

 ln
 
spost0t

(2.12)
where sante0t and s
post
0t denote the share of the outside good at time t under the current
45 In the case of endogenous entry, consumer welfare will depend on the choices made by the
“me-too” innovators.
38
and modified policies, respectively. The total discounted welfare change is then
CV 
T¸
t1
CVt  p1  d
cqt1 (2.13)
where dc is the rate at which consumers discount utility.
While consumers pay only a fraction of the full drug prices, the rest of the price
is paid by insurers. Therefore, insurer savings from the switch to the modified policy
is given by
Πins 
T¸
t1
#
J¸
j1

ppantejt  c
ante
jt qs
ante
jt  pp
post
jt  c
post
jt qs
post
jt

Mt  p1  d
cqt1
+
, (2.14)
where the terms identified as ante and post correspond to the equilibrium prices
and shares under the current and modified policies, respectively. Note that the
insurers, like the consumers, are payers and so their expenditures are discounted by
the consumer rate, dc.
For the producers’ net total welfare effect (innovators and generic manufacturers),
the difference of each producer’s profit under the current and modified policies is
summed across all producers and discounted to time t  1. That is,
Πdiff 
T¸
t1

F¸
f1
 
Πpostft  Π
ante
ft

 p1  df qt1
ff
, (2.15)
where df is the rate at which producers discount profits, and Πanteft and Π
post
ft are
producer f ’s profit (calculated according to equation (4.5)) under the current and
modifed policies, respectively.
For simplicity in implementing the simulations of the modified patent policies,
I use the averages over time of both implied marginal cost, mcj, and unobserved
product heterogeneity, ξj, for each product j.
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Results under Exogenous Entry
Prozac entered the antidepressant market in January 1988 and its patent expired
in July 2001. This means that Prozac enjoyed an effective patent life of 13.5 years.
During its patent-protected time on market, three other SSRI drugs entered the
market: Zoloft, Paxil, and Celexa. I assume that these are “me-too” drugs, and
restrict them from the market until Prozac’s patent expires under the modified policy.
Under the original policy, I then calculate the present discounted profits generated by
Prozac while under patent protection. This amount is then set as the minimum profit
requirement under the modified policy. Given the restriction under the modified
policy, I find that Prozac’s innovator, Eli Lilly, is able to earn at least the same
present discounted profits with a patent that expires in September 1995.46 This is
a difference of nearly six years (70 months) or a 43% reduction in Prozac’s effective
patent life.
The impact of the policy switch on the “me-too”s is shown in Table 4.2. The
effective patent life for Zoloft and Paxil is shortened by 3.58 years and 2.67 years,
respectively. This is roughly a 25% reduction in the patent protected time on market
for both drugs.47 On the other hand, Celexa entered the market in August 1998 and
so its effective patent life is unaffected. Once on the market, the “me-too” drugs
compete against both Prozac and its generic variants (fluoxetine). Discounted to
January 1991, Zoloft experienced a $2.9 billion loss in profit (63% reduction) due
to its delayed entry and competition against generic fluoxetine. For Paxil, this loss
was only $621 million, but this amounts to more than 75% of its profit under the
original policy. The impact on Celexa is exclusively from its competition with generic
fluoxetine. The last row in Table 4.2 shows the impact of the generic versions of each
46 Note that time in my data is in increments of months.
47 While Paxil entered the market several months after Zoloft, its patent expired nearly four years
before Zoloft’s. See Table 4.1.
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of these “me-too” drugs, which are fairly insignificant, amounting to less than 1% of
their respective profits.
Table 4.3 provides the total effect for each segment of the market. Under the
counterfactual simulation, Prozac earned an additional $16 million, primarily due
to the discreteness of time in setting the new patent length. The impact of the
policy switch generated more than $4 billion in additional profits for producers of
generic fluoxetine. Note that I assume that the number and relative timing of en-
try among the generic fluoxetine producers remains the same. The overall timing
is simply advanced to the new patent expiration date for Prozac.48 Additionally,
the generic products are differentiated products on the market and generally price
above marginal cost. The total impact for “me-too” brands and generics are simply
the totals of the figures in Table 4.2. As expected, the impact on the rest of the
products in the market is nearly insignificant. Interestingly, the net impact across
all producers is a gain of only $36 million. Allowing additional generic entry on
fluoxetine would then reduce their super-normal profits and lead to a large and neg-
ative net impact across all producers. However, this potential negative impact on
producers is overshadowed by the substantial savings by insurers, more than $10.2
billion (a 14.4% reduction in expenditures). This is due to the substantially lower
cost to insurers when consumers purchase generics over brand name products and
with the advanced timing of generic entry on Prozac. Finally, this advanced timing
of generic entry also results in a small net gain to consumers, despite the broadening
of Prozac’s market exclusivity to temporarily restrict the entry of “me-too”s. The
overall effect on social welfare is a $10.5 billion gain.
The above policy experiment addresses the current debate in the pharmaceutical
48 For example, consider two generic firms, A and B, where Firm A enters two months before Firm
B. Under the counterfactual, Firm A will still enter two months before Firm B, even though overall
both enter the market earlier.
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literature on limiting the incentives of “me-too” drugs. This is achieved by modifying
the patent breadth and length of the high-value innovation and maintaining the same
entry decisions for subsequent entrants. For the second policy experiment, I relax
this assumption on the entry decisions by “me-too” innovators. This provides a more
robust approach to estimate the social welfare impact.
2.7.4 Endogenous Entry
Entry Re-optimization
I now consider the impact of allowing “me-too” innovators to re-optimize their de-
cision to enter Phase III clinical trials under the modified policy.49 I implement this
by focusing on innovators that were observed to enter the market under the current
policy and comparing their entry costs to their expected profits. Hence, an inno-
vator will save its investment costs of Phase III if it chooses not to continue. For
simplicity, I assume that entry of previously unseen products does not occur under
the modified policy. Under the current policy, innovators enter in a sequential order
f 1, ..., fn and then realize profits Π1,ante, ...,Πn,ante, respectively. It is also assumed
that this order reflects the order in which innovators reach their decision point at
the end of Phase II clinical trials. Finally, I assume a full information game where
innovators see the product qualities, development costs, and time to market entry
of all the other potential market entrants. Therefore, innovator f can anticipate the
impact of the modified policy on the timing of when product j would be allowed to
enter the market.
Let Cfj be innovator f ’s fixed Phase III clinical trial costs for product j and
assume Cfj  FNpµ, σ2|0 ¤ κ   Cfj   V antefj q, where Cfj is independent across
innovators and products, V antefj is innovator f ’s net present discounted profit from
49 As discussed in Section 2.3.1, innovators gain significant information on the safety and efficacy
of their innovations during Phase II of clinical trials. I assume that this is sufficient to make an
informed decision.
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product j under the current policy, κ is a lower bound on costs, and FN is a truncated
normal distribution:
FN 
Φp
Cfjµ
σ
q  Φpκµ
σ
q
Φp
V antefj µ
σ
q  Φpκµ
σ
q
. (2.16)
Innovator f will choose to send product j to Phase III clinical trials under the
modified policy if Cfj   V
post
fj , where V
post
fj is innovator f ’s net present discounted
profit from product j under the modified policy.50
In order to estimate the probability of each possible market outcome under the
modified policy, I apply the following simple algorithm:
1. Draw Cfj for each product.
2. Determine the re-optimized decision for each product using backward
induction.
3. Repeat Steps 1 and 2 N times.
4. Finally, calculate λn, the probability of each possible market outcome,
n  1, ..., N .
When simulating the entry re-optimization, I use estimates (in December 2010
dollars) calculated by DiMasi et al. (2003) for average Phase III costs, µ  $143
million, and standard deviations, σ  $118 million, for approved drugs. DiMasi
et al. (2003) also estimated that the average length of time from the start of Phase
III to drug approval is 52 months. I use this estimate to calculate Vfj for innovator
f and product j. Finally, I set κ to be $1 million.
Social Welfare under Endogenous Entry
The social welfare calculation under endogenous entry is a simple analog of the
exogenous case that includes probability weights for the N market outcomes. The
50 Given that these products were approved by the FDA under the current policy, they would still
be approved under the modified policy. The question is merely one of timing if products continue
on to Phase III.
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equations corresponding to (4.2)-(4.6) for the counterfactual with endogenous entry
for “me-too”s are given by:
CVt,n  
Mt
α

ln
 
sante0t

 ln
 
spost0tn

, (2.17)
CV 
N¸
n1
λn

T¸
t1
CVt,n  p1  d
cqt1
ff
, (2.18)
Πins 
N¸
n1
λn

T¸
t1
#
J¸
j1
 
pantejt  c
ante
jt

santejt 
 
ppostjtn  c
post
jtn

spostjtn

Mt  p1  d
cqt1
+
,
(2.19)
and Πdiff 
N¸
n1
λn
#
T¸
t1

F¸
f1
 
Πpostftn  Π
ante
ft

 p1  df qt1
ff+
. (2.20)
Let IPhaseIIIjn be the expenditure saved when innovation j is abandoned rather than
taken to Phase III clinical trials, discounted to time t  1 using the rate df . The
total expenditure saved across all such abandoned innovations is given by
IPhaseIII 
N¸
n1
λn

J¸
j1
IPhaseIIIjn

. (2.21)
Finally, the discounted social welfare effect is then given by
SC  CV   Πins   Πdiff   IPhaseIII . (2.22)
Results under Endogenous Entry
As before, the “me-too” drugs may enter the market starting in September 1995.
The first two rows of Table 4.4 provide the lower and upper bound values that
plugged into the truncated normal distribution in equation (4.7). To calculate the
upper bound, the net present profit of each product is discounted back to the start of
Phase III clinical trials. This is assumed to be 52 months prior to the orginal market
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entry date for all products. Note that all of the products have an upper bound that
is substantially higher than the distribution mean of $143 million. The average and
standard deviation of draws from step (1) of the algorithm are given in the middle
two rows of Table 4.4. Given that the “me-too” innovators make their decisions in
sequential order, backward induction is used to determine the market outcome for
each set of cost draws. The probability of entry for each drug is provided in the fifth
row of the table. Zoloft will always go into Phase III clinical trials and eventually
enter the market, while Celexa and Paxil will do so 88% and 48.5% of the time,
respectively. The saved expenditure weighted by market outcome is given in the last
row of the table.
The impact of the policy switch on the “me-too”s is shown in Table 4.5. The first
row matches the results in the first row of Table 4.2. Intuitively, it is expected that
profit loss for the “me-too” brands would be lower, given the ability to reoptimize the
entry decision. This can be seen by summing the saved expenditure and the change
in product profit. The impact on the “me-too” generics is more dependent on the
entry decisions by the corresponding innovators. If a brand product is abandoned by
its innovator, generic entry on that molecule is assumed to never occur. Interestingly,
while generics of Paxil experience substantial losses, those on Zoloft actually benefit.
This is likely due to the reduced level of competition when generic versions of Paxil
do not enter the market.
The net welfare effect for each segment of the market is provided in Table 4.6.
This time, the impact on generic versions of Prozac is larger due to the limited
competition when the other “me-too” products are abandoned. The fourth and fifth
rows of the table show that the other products on the market also enjoy this benefit.
Overall, the producers gain nearly $149 million in direct profit. By abandoning their
products, these innovators also saved $127 million in Phase III expenditures. Not
surprisingly, insurer saving are also larger under the modified policy with endogenous
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entry, reflecting the higher consumption of generic fluoxetine. The consumers welfare
calculation shows that consumers still prefer the modified policy, but that their
benefit is tempered by the decrease in products variety on the market. Overall, the
social welfare gain is nearly $11.4 billion, which is larger than the modified policy
with exogenous entry.
2.8 Conclusion
This paper provides the first empirical assessment of the trade-off between patent
breadth and patent length. I draw on key insights from the theoretical literature,
which highlights the importance of the market structure and shape of the demand
curve in determining optimal patent policy. I first estimate demand parameters to
determine insured consumers’ product substitution patterns. Incorporating the esti-
mated demand parameters into a model of supply, I then back out firms’ marginal
costs of production, allowing me to perform counterfactual analyses. I use 20 years
of retail prescription sales data on the market for antidepressants along with adver-
tising, targeted to physicians and nurses, for each drug. Demand estimates indicate
that consumers consider products within each therapeutic class to be much closer
substitutes than those across classes.
Using estimates from the static models of demand and supply, I consider two
policy simulations. The first modifies the patent of the first-in-class groundbreaking
drugs to address the debate in the pharmaceutical policy literature on the value of
limiting the development of “me-too” drugs. Specifically, I expand the patent breadth
and limit the patent length of the groundbreaking antidepressant drug, Prozac, in
order to temporarily restrict the subsequent “me-too” products from entering the
market. Estimates show that under this modified policy, Prozac is able to generate
equivalent net present discounted profit under patent protection with an effective
patent length that is 43% shorter than under the original policy. Assuming all “me-
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too” products eventually enter the market, I find small welfare gains for producers
and consumers along with substantial gains to insurers in the form of expenditure
savings. Even if gains by manufacturers of generic Prozac (fluoxetine) were ignored,
the net social effect is still positive.
The second policy simulation extends the first, by allowing the “me-too” inno-
vators to anticipate the impact of the modified policy and reoptimize their entry
decisions during their respective drug development processes. Those innovators that
abandoned their drugs save their remaining investment expenditures. Through sim-
ulations, I find that while Zoloft would always proceed through Phase III clinical
trials and onto the market, Paxil and Celexa would only do so with probabilities of
48.5% and 88%, respectively. As expected, producers’ welfare improves with their
ability to reoptimize their entry decisions. In cases where the products do not enter
the market, consumers lose the value of “me-too” entry as well as the generics that
would have followed on each molecule. However, this loss is still overshadowed by
the gain of earlier generic entry on fluoxetine. Insurers now realize even greater gains
as consumers who would have otherwise purchased Paxil and Celexa, turn to generic
fluoxetine instead.
My results indicate the potential for meaningful social gains from exploring mod-
ified patent policies. A weakness is that while the assumptions simplify the problem,
some also limit the generalizability of my conclusions. For example, I abstract away
from any uncertainty consumers may have of the quality of new products introduc-
tions. If consumers learn about this quality from each other, then the higher coun-
terfactual price on Prozac would induce more price-sensitive consumers to switch
to generic versions. In turn, this would speed up consumers’ learning process as
well as the adoption rate of these generics. Therefore, the modified patent policy
could potentially further increase the competitive pressure on Prozac’s innovator af-
ter patent expiration. A second example is that it is unlikely that insights from this
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analysis can be extended to the biologics (large molecules) segment of the industry,
given that their innovation and patenting is conducted differently. However, the pol-
icy framework may be applicable to other industries like chemicals and agriculture,
where innovation costs may be high relative to imitation costs, and secrecy provides
insufficient protection due to the possibility of reverse engineering.
To allow for a more robust policy framework, many of these assumptions can be
relaxed. Chief among these is the assumption that all products that follow the first-
in-class drug provide only an incremental benefit. Ongoing research allows the FDA
(or another independent agency) to formalize the distinction between high-value and
“me-too” drugs according to a clearly defined margin of value. Thus, high-value
innovators that may be second-in-class or later observe clear guidelines necessary to
enter the market without additional delay. To limit the inherent risk for products
that are in close competition to be first-in-class, a compromise may allow the second
innovator to enter the market without delay if it reaches the FDA review within some
period of time after the first-in-class molecule (Hollis, 2004). It is left for future work
to examine the effects of relaxing other assumptions, including those restricting the
dynamic behavior of insurers and other market participants.
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Figure 2.2: Area Plot of Monthly Quantity Sales by Therapeutic Class with Stan-
dardized Daily Doses: January 1991 – December 2010
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Figure 2.3: Area Plot of Monthly Quatity Sales for the Top SSRI Molecules with
Standardized Daily Doses: January 1991 – December 2010
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Table 2.2: Copay Regressiona
Regressor Coefficient Std. Err.
φ 0.4277 (0.0189)
brand (binary) 0.5885 (0.0135)
γ0 0.3607 (0.0795)
a
Dependent variable is cjt. Estimated
at the patient-prescription-month level.
Based on 194,367 observations. Copays
are taken from insurance plan listings.
Heteroskedasticity-robust standard errors
are reported.
Table 2.3: IV Regression Results a
Regressor Coefficient Std. Err. Coefficient Std. Err. 1st Stage F-Stat.
nest parameters
ln(molec. share of class) 0.5574 (0.0295) 70.1
ln(prod. share of molec.) 0.6504 (0.0238) 77.6
copay -4.5683 (0.3591) 127.7
ln(detailing) 0.0582 (0.0095)
brand (binary) 2.8652 (0.2016)
Months on Mkt Interacted w/ SSRI
Month 1 -0.4817 (0.6365) -2.6344 (0.6699)
Month 2 -0.4716 (0.6338) -1.2171 (0.6489)
Month 3 -0.4673 (0.6442) -0.7420 (0.6570)
Month 4 -0.4693 (0.6441) -0.5286 (0.6540)
Month 5 -0.4582 (0.6561) -0.4075 (0.6645)
Month 6 -0.4916 (0.6325) -0.3018 (0.6407)
Month 7 -0.4788 (0.6271) -0.5409 (0.6471)
Month 8 -0.4782 (0.6340) -0.3543 (0.6415)
Month 9 -0.5260 (0.6079) -0.2320 (0.6138)
Month 10 -0.5061 (0.6230) -0.1852 (0.6275)
Month 11 -0.4738 (0.6310) -0.1679 (0.6348)
Month 12 -0.6328 (0.4272) 0.0245 (0.4338)
a
Dependent variable is lnpsjtq lnps0tq. Based on 31,872 observations. All standard errors are clustered
at the quarter-molecule level.
55
Table 2.4: Price Elasticities: January 1995
Class Molecule Own-Price Elasticity NGA SSRI
NGA bupropion hcl -2.4468 0.2602 0.0722
NGA nefazodone hcl -3.1590 0.2756 0.0722
NGA trazodone hcl -1.6101 0.4183 0.0722
NGA venlafaxine hcl -2.4716 0.1927 0.0722
SSRI fluoxetine hcl -1.7482 0.0045 0.4385
SSRI paroxetine hcl -2.9028 0.0045 0.7780
SSRI sertraline hcl -2.1597 0.0045 0.8006
a Source: SDI Monthly Data over the period 1991 to December 2010.
The elasticity in the ith row and jth column is the average demand
elasticity across products in molecule i with respect to the price of
products in nest j.
Table 2.5: Impact of Modified Policy on “Me-Too” Drugs with Exoge-
nous Entry
Change in Levels Percentage Change
Change in: Zoloft Paxil Celexa Zoloft Paxil Celexa
effective patent lifea -3.58 -2.67 0 -23.9% -25.6% 0.0%
PV(brand profit)b -2932 -621 -204 -62.8% -75.2% -55.8%
PV(generic profit)b -1 -4 -1 -0.2% -0.9% -0.5%
a Effective patent life is in years.
b All dollars are in millions and discounted to January 1991 with a rate of 11%.
Table 2.6: Present Value Welfare Under Ex-
ogenous Entry
Change In Dollarsa % Change
Prozac profitb 16 0.6%
generic Prozac profitb 4042 275.4%
‘me-too’ brand profitb -3794 -64.0%
‘me-too’ generic profitb -6 -0.5%
other SSRI profitb -39 -2.4%
other non-SSRI profitb -183 -2.0%
all firms’ profitb 36 0.1%
insurer savingsc 10202 -14.4%
consumer welfarec 312 1.6%
social welfare 10550 9.4%
a Dollars are in millions and discounted to January 1991.
b Firms’ profits are discounted at 11%.
c Insurer savings and consumer welfare are discounted at
5%.
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Table 2.7: Distribution Bounds and
Average Costs of Phase III Clinical
Trialsa
Zoloft Paxil Celexa
lower boundb 1 1 1
upper boundb 3198 630 630
mean(cost)c 169 170 168
sd(cost)c 98 99 98
Prob(entry)c 100% 48.5% 88.0%
IPhaseIII – 113 14
a All dollar values are in millions.
b Lower and upper bounds of the products’ re-
spective truncated normal distributions. The
upper bounds are calculated as the net
present value profit of each product, dis-
counted to the start of Phase III clinical trials,
52 months prior to market entry.
c Based on 10,000 random draws for each prod-
uct.
Table 2.8: Impact of Modified Policy by Moleculea
Change in Levels Percentage Change
Change in: Zoloft Paxil Celexa Zoloft Paxil Celexa
effective patent lifea -3.58 -2.67 0 -23.9% -25.6% 0.0%
PV(brand profit)c -2864 -725 -254 -61.3% -87.8% -59.0%
PV(generic profit)c 35 -237 -18 7.6% -51.2% -6.8%
a Effective patent life is in years.
b Phase III clinical trial costs are weighted by entry decisions and then discounted or
inflated to January 1991.
c Profits are calculated according to equation (4.11), then weighted by entry decisions
and discounted to January 1991. All dollars are in millions.
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Table 2.9: Present Value Welfare Under En-
dogenous Entry
Change In Dollarsa % Change
Prozac profitb 16 0.6%
generic Prozac profitb 4226 287.8%
‘me-too’ brand profitb -3844 -64.9%
‘me-too’ generic profitb -220 -18.5%
other SSRI profitb 85 5.2%
other non-SSRI profitb -113 -1.3%
all firms’ profitb 149 0.6%
saved expenditureb 127
insurer savingsc 10905 -15.4%
consumer welfarec 194 1.0%
social welfare 11375 10.1%
a Dollars are in millions and discounted to January 1991.
b Firms’ profits are discounted at 11%.
c Insurer savings and consumer welfare are discounted at
5%.
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3Pharmaceutical Insurance and Generic Entry
3.1 Introduction
We explore how generic-drug availability differentially affects insured and uninsured
consumers. Simple logic suggests that generic drugs particularly benefit uninsured
consumers. However, we show that this logic might be wrong, because generic prices
fall slowly for uninsured consumers, while insurance copayments fall immediately
upon generic entry. Being labeled a generic and having a price below the branded
drug are sufficient conditions for the insurance copayment to fall, while it is only
through competition that the generic price falls. Hence, at least initially, generic
entry disproportionately benefits insured consumers.
An extensive literature documents how drug demand responds to prices and ad-
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vertising1 as well as to insurance.2 We make three contributions to the literature.
First, we show how generic availability differentially affects people based on insur-
ance coverage. Second, we account for drug price competition within class and across
classes using data on prices and copayments. Finally, we model why branded prices
might increase in the face of generic competition.
First, we show how generic availability differentially affects people based on in-
surance coverage. Immediately after generic entry, copayments fall by more than
50%, while generics often provide only a small discount during the first year (Figures
3.3 and 3.4).
Second, we account for drug price competition within class and across classes. We
have monthly data on prescription and over-the-counter prices, as well as insurance
copayments for two classes of drugs for fifteen years (1996-2010). Accounting for
insurance copayments is a critical component of our analysis. Health care markets are
rather distinct in that the price paid by insured consumers (copayment) is typically
much smaller than the price received by the manufacturer. With these price data,
we estimate elasticities using a discrete choice model similar to Berry et al. (1995).
Finally, we model why branded prices might rise in response to generic competi-
tion. Scherer (1993) described this as the “generic paradox” because it is surprising
1 See Gemmill et al. (2007) and Baicker and Goldman (2011) for surveys of the literature on
drug demand and elasticity. After estimating demand, other studies also estimated the welfare
implications of pharmaceutical competition, including Chaudhuri et al. (2006); Granlund (2010);
Branstetter et al. (2011); Dutta (2011); Arcidiacono et al. (2013); Bokhari and Fournier (2012);
Dubois and Lasio (2013); Taylor (2014). In particular, Arcidiacono et al. (2013) estimate the
welfare effects of competition among manufacturers of the same molecule, among manufacturers of
different molecules in the same class, and among manufacturers of different molecules in different
classes. Our paper is unique in estimating the differential effects of generic availability on prices
and welfare, according to insurance status.
2 Expanding health insurance can affect both the quantity and price of health care. Regarding
quantity, both the RAND health insurance experiment (Manning et al., 1987) and the Oregon
health insurance experiment (Baicker et al., 2013) show that expanding health insurance increases
health care consumption, but does not necessarily improve health outcomes. Regarding price, while
insurance makes consumers less sensitive to price (Pauly, 1974), insurers sometimes have negotiating
power over manufacturers and can drive down prices (Duggan and Scott Morton, 2010), particularly
in drug classes with close substitutes (Ridley, 2014).
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that a manufacturer would raise prices when faced with new competition.3 One ex-
planation for the paradox is that a branded manufacturer’s profit-maximizing price
path is increasing because of consumer learning about quality (Ching, 2010a) and
while generic entry causes prices to fall relative to trend, prices nonetheless increase
relative to previous periods (Bhattacharya and Vogt, 2003). Another explanation
for the generic paradox is that the mix of consumers changes after patent expiration
with some consumers switching to generics (Frank and Salkever, 1997). Because we
have patient-level data and a structural model, we can create micro moments for
patient types and simulate how the profit-maximizing price rises when generic drugs
enter the market.
The rest of the paper proceeds as follows. In the next section, we provide back-
ground on the antiulcer market and show how it evolved over time. Section 3.3
then describes the demand model and estimation procedure. We present the supply
model in Section 3.4. In Section 3.5, we describe the results and their implications
for elasticities and producer marginal costs. Lastly, Section 3.6 concludes.
3.2 Background and Data
We examine the “antiulcer” market, as in several previous economic analyses (Berndt
et al., 1995, 2003; Arcidiacono et al., 2013; Ridley, 2014). The antiulcer market con-
sists of drugs that treat ulcers as well as acid reflux (“heartburn”). Approximately
10-20% of people in the United States have reflux (Fedorak et al., 2010), and ap-
proximately 1% have gastric ulcers (Kurata and Haile, 1984). The therapeutic class
of drugs known as H2 antagonists (H2s) were the first to enter the antiulcer market,
and were followed by the proton pump inhibitors (PPIs). H2s work by blocking his-
tamine receptors on acid-secreting cells in the stomach lining to inhibit peptic acid
3 Caves et al. (1991) estimated a negative relationship, while Grabowski and Vernon (1992) esti-
mated a positive relationship between generic entry and price. For example, Regan (2008) found a
1-2% increase in price associated with generic entry.
61
production. Working more directly than H2s, PPIs inhibit the proton acid pump in
the lining of the stomach.4
Antiulcer drugs are generally seen as close substitutes by the scientific community,
including the FDA which granted priority review to only the first H2 and the first
PPI. However, manufacturers of the later products to enter the market assert that
their drugs are superior, or at least different, and thus should not be thought of
as me-too drugs. For example, the manufacturer of Zantac (the second H2) claims
at least five advantages over the first mover, including lower relapse rates, fewer
side effects, and more indications (Berndt et al., 1995). Likewise, the fifth PPI,
Nexium, is advertised as the “healing purple pill”. The FDA-approved label reads:
“Nexium 40mg demonstrates higher healing rates in erosive esophagitis than Prilosec
20mg (the approved dose for this indication)”. Hence, while the FDA regards the
drugs as close substitutes, the manufacturers of these later entrants claim otherwise.
Ultimately, the question is whether doctors and patients consider these drugs to be
close substitutes. We use a revealed preference approach to investigate the sensitivity
of demand to price differences across the drugs, and the welfare effects of newly-
available drugs, including generic versions of existing brand name products.
The first H2s came off patent early in our sample period, while the three most
recent PPIs remain on patent at the end. Branded H2s entered from 1977 to 1988
and began facing generic competition in 1994 (see Table 3.1). By 2001, all branded
H2s faced generic competition, with cimetidine and ranitidine each having more than
thirty generic manufacturers. Branded drugs in the PPI class entered between 1989
and 2009 with generic entry beginning in 2002.
4 While the antiulcer drugs are indicated for short-term treatment, they can be used considerably
longer. For example, Nexium is indicated for treatment of heartburn and other symptoms associated
with GERD. Its FDA-approved label says that it is indicated for short-term treatment (4 to 8 weeks)
in the healing and relief of symptoms associated with erosive esophagitis. However, the label also
says that Nexium may be used for additional weeks if the patient has not yet been healed and that
the use of Nexium may be continued to maintain the healing.
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To capture this market in our analysis, we primarily rely on three data sets. The
first is the MarketScan data, which provide a sample of patient-prescription level
purchases provided by large employers. Ranging over the period 1996 to 2009, this
data allows us to track patient purchases over time.
The second data set was purchased from SDI Health (later acquired by IMS
Health) and it provides sales and advertising. The sales data is comprised of monthly
prescription drug sales from U.S. retail pharmacies between October 1993 and De-
cember 2010. This data include units (for example, number of pills), prescriptions,
dollar value, and whether the purchase was done through an insurance plan or paid
for out-of-pocket. An important limitation of this data is that the breakout by pay-
ment type only starts with January 1996. The advertising data include expenditures
targeted at physicians, often referred to as detailing, at the molecule-manufacturer-
month level.
Finally, we use information on copayments (the prices consumers face) provide by
AdvancePCS, a pharaceutical benefit plan administrator. For a subset of years, the
data include copayment by molecule-insurer-month for a subset of the years. The
copayment data and details of the insurance market are described below.
3.2.1 Prescriptions
In our analysis, we use retail prescription sales adjusted to daily doses.5 Figure 3.1
illustrates the evolution of the market’s composition by molecule and brand/generic
(B/G) status, and shows the relative consumption by molecule. Here, prescriptions
are aggregated across all generic manufacturers of the same molecule. Prior to 1993,
5 The market we examine is restricted along two dimensions. First, we focus on retail sales rather
than hospital sales. From 2003 to 2010, retail sales accounted for 91% of PPI prescriptions. We were
able to compare retail to hospital sales using another data set with less periodicity (annual rather
than monthly) and a shorter time period (2003-2010 rather than 1991-2010). Second, we focus on
prescription medications rather than the over-the-counter market. According to an analyst report,
over-the-counter drugs accounted for 16% of the retail PPI market from February 2009 to February
2012. Section 3.3.4 describes how we account for over-the-counter availability in our estimation.
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H2s controlled the market, with branded ranitidine (Zantac) as the market leader,
accounting for over half of all prescriptions. In the mid 1990s, branded omeprazole
(Prilosec, the first PPI) became the market leader. Later, branded lansoprazole
(Prevacid, the second PPI) became the market leader. In the last five years of the
sample, omeprazole (now available as a generic) had a quarter of the market, as did
esomeprazole (available exclusively as the branded drug Nexium), with the remaining
half of the market distributed across various H2s and PPIs.
Figure 3.1 illustrates the quick growth in the PPI market. The PPI market grew
rapidly in part by stealing from the H2 market as can be seen in the decline of the
H2 market. However, the total prescription anti-ulcer market was clearly expanding.
New entrants to the PPI market advertised heavily. Also, new patients might have
entered the market, for instance to seek relief from ulcers caused by non-steroidal
inflammatory drugs. Finally, generic entry increased access by dramatically reducing
prices (Figures 3.3 and 3.4). With lower generic prices, branded share eroded rapidly.
For example, six months after the entry of generic ranitidine, the branded share had
fallen by 90%. The impact was similar for the remaining H2s and the PPIs with
generic versions. Nonetheless, branded drugs maintain a small segment of the market
for a few years after initial generic entry.
The overall evolution of market shares is different for PPIs and H2s, reflecting
differences in both business stealing and market expansion. H2 prescriptions peaked
in 1995 at just over 3.5 million, but declined steadily thereafter as more PPIs were
brought to market. However, combined prescriptions for H2s and PPIs rose dramat-
ically, from just over 2.25 million in 1991 to 9 million by 2011.
Preferences for particular forms may also be important, as the side effects and
release times can vary between tablets and capsules.6 Nizatidine and famotidine have
6 Breitkreutz and Boos (2011) note that oral forms (i.e. tablets and capsules) are generally
preferred, but some patients might not find them easy to swallow, and also note that different
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similar branded shares in the 1990s, but dissimilar generic shares in the 2000s. The
difference occurs when PPIs are becoming bigger players. A possible explanation
for generic famotidine outpacing generic nizatidine is that PPIs are generally of the
same form (capsule) as nizatidine and are therefore better substitutes.
3.2.2 Insurance
Insurance complicates the standard demand and supply framework. Insured con-
sumers typically pay a fraction of the total retail prices, while the insurers pay the
rest. This reduces the price sensitivity of these consumers and expands the market.
However, not all consumers are insured. As shown in Figure 3.2, the proportion of
the U.S. population that was uninsured during the years 1996 to 2009 fluctuated be-
tween 13% and 16%. This can then be compared to prescriptions sales purchased with
cash. These purchases appear fairly stable between 1996 and 2003. Cash purchases
fall after 2003 due to at least two factors. First, in 2003 the first over-the-counter
PPI is introduced. Cash payers might switch from prescription to over-the-counter.
Second, beginning in 2006 Medicare beneficiaries have the option of drug coverage
under Medicare Part D, so fewer must pay cash.
3.2.3 Prices
Our price data include the average price per prescription (revenue divided by pre-
scriptions), the wholesale acquisition cost (a list price), and the copay. We have only
retail sales data, but retail accounts for 90% of the market for antiulcer drugs. All
prices are adjusted to January 2010 dollars.
Figures 3.3 and 3.4 illustrate prices (solid lines) and copayments (dashed lines) for
patients can have different sensitivities to inactive ingredients (which can vary across forms). Jones
and Francis (2000) find that, when comparing tablets to capsules, the relative ease of swallowing,
perceived speeds of action, and perceived durations of action can all vary from patient-to-patient.
As the authors conclude, “consumers have preferences for particular dosage forms.”
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brands (purple) and generics (green) in the H2 and PPI classes.7 Typically, branded
prices are flat or increasing while generic prices are falling over time. For example, the
price of branded cimetidine was approximately $100 in 1994, while generics entered
with a price near $75. Over time, the branded price climbed to nearly $150, while
the generic price fell below $20. The decline in generic prices might be explained
by an increase in generic competition over time, or by falling marginal costs due to
learning-by-doing in production. The fact that branded prices do not fall (and often
rise) despite the collapse of their market shares suggests the relevant competitive
adjustment occurs along a different dimension. From Figure 3.1, however, the fall
in H2 generic prices does not appear to be associated with increased prescriptions.
This suggests the rise of PPIs — in addition to expanding the prescription market
— results in fewer generic prescriptions.
Insured consumers realize the benefit of generic entry through an immediate
and often significant reduction of their copays through their insurance plans. The
formularies used by these plans generally list a predetermined copay amount that
applies to all generic prescription products. Hence, the cost to insured consumers is
independent of any competitive behavior beyond generic entry. Figures 3.3 and 3.4
depict these copay prices as dotted lines. The generic copay is significantly lower than
the corresponding brand price. For example, it takes 33 months after omeprazole’s
patent expires for the retail value to match a proportional drop in price observed in
the copay value with generic substitution (Figure 3.4a).
In contrast, uninsured consumers benefit little initially from generic entry, be-
cause at the outset the generic price is close to the branded price (while the generic
copay is half the branded copay). Only after months or years do competitive forces
cause a decrease in generic price. Hence, the initial benefit from lower prices for unin-
7 In Figure 3.3a, the branded price and copay end in 2007, because the branded manufacturer
(though not the generic) exits. In Figure 3.3b, the branded price ends because it is truncated at
$180 and we want to maintain the same scale across figures.
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sured consumers is modest, but grows over time. For example, Figure 3.4a illustrates
the prices for both branded and generic 20 mg omeprazole over time. The patent for
omeprazole expired in October 2002. The following month, the first generic producer
entered the market and immediately began to offer a retail price below the brand
producer (solid lines). Two other generic producers entered the market six months
later and another three months after that, further competing down the price. The
count of generic producers increased to five by 2005 and to eight by 2009. As shown
in Figure 3.4a, the average generic retail price continued to decrease throughout this
period.
3.3 Demand
3.3.1 Theory
We use a discrete choice model similar to one developed by Berry et al. (1995) to
estimate demand in the pharmaceutical market. We start by defining the conditional
indirect utility that consumer i obtains from product j, uijpθq, as a function of
product and consumer characteristics, both observed and unobserved, as well as
model parameters θ. The utility function is written as
uijpθq  δjpθ1q   µijpθ2q   εij, (3.1)
where δjpθ1q is a product-specific term common to all consumers, µijpθ2q captures
consumer taste heterogeneity for observed product characteristics, and εij is the error
term, which is assumed to be i.i.d. across both products and consumers. We assume
consumer i chooses the product j that yields the greatest utility. Aggregating over
all consumer choices then allows us to obtain market shares.
The first component from this equation, δjpθ1q, is common to all consumers and
given by
δjpθ1q  Xjβ   ξj, (3.2)
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where Xj is a vector of observed product characteristics, β is a vector of mean taste
parameters associated with those characteristics, and ξj represents the unobserved
(by the econometrician) product utilities.
The second term in the above utility function captures the variation in utility by
consumer types across observed characteristics and is given by
µijpθ2q  αipj  
¸
ν
¸
k
γνkIpi P νqxjk. (3.3)
Given that pharmaceuticals are relatively cheap products, we assume away any in-
come effects and interpret αi to be consumer i’s dis-utility of price. The kth charac-
teristic of product j is given by xjk and consumer i is part of a consumer segment,
indexed by ν and identified by Ipi P νq, that have common tastes for the observed
characteristics.8 Let τν denote the probability that consumer i is a type ν. We as-
sume that consumers know their respective types, but the econometrician does not.
These terms are then interacted with γνk, a parameter measuring the heterogeneity
across consumer types in tastes for the observed characteristics in the population.
3.3.2 Prices and Copayments
The pharmaceutical industry differs from nearly all other industries in that the pa-
tient often pays only a small fraction of the cost of the drug, or copay, while the
insurance companies pay the rest.9 One of the dimensions in which insurance com-
panies compete is through the copay amounts that they set for the drugs available
on the market. Hence, we first use the MarketScan data to estimate the relationship
between the prices charged by the firms, pj, and the copay paid by the patient, p
c
j,
in the form
lnppcjq  α
c lnppjq  Xjβ
c   εcj, (3.4)
8 This approach differs from that in Berry et al. (1995), which allows for consumer-level hetero-
geneity rather than restricting it to a consumer group level.
9 The doctor prescribing the drug and the patient together are assumed to be the consumer.
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where εcj is i.i.d. across products. Next, we calculate the market-level variance-
covariance matrix of drug copays, V c, from insurance company listings for each
drug over time. Taking draws from a standard normal distribution the Cholesky
decomposition of V c then allows us to adjust consumers’ price, pcj, to reflect consumer
types. We can thus capture the fact that consumers in a given insurance plan face
a particular menu of prices. In our setting, the random coefficient on price captures
this particular form of heterogeneity across consumers. Note that the shape of this
heterogeneity is directly informed by the auxiliary dataset on insurance plans.
We restate the utility specification to reflect the substitution patterns among
pharmaceutical drugs. Consumer i chooses the drug j that maximizes
uij  αφipp
c
jq  Xjβ  
¸
ν
¸
k
γνkIpi P νqxjk   ξj   εij, (3.5)
where φipq is the linear function that adjusts consumers’ prices with draws from the
Cholesky decomposition of V c.
3.3.3 Estimation
Based on the approach of Berry et al. (1995), our estimation strategy follows the
approach taken by Petrin (2002), who combined both macro (aggregate) and micro
(individual) moments to better pin down consumer heterogeneity.
Micro Moments
The MarketScan data are used to generate micro moments (averages) that improve
the demand estimation. The GMM estimation routine works by adjusting the pa-
rameter estimates so that the average model predictions will match the observed
averages from the MarketScan data. In this way, the estimation is improved with
the number of distinct micro-moments that are included (Petrin, 2002).
We use a set of three moments to capture the persistence of consumer purchases
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over time. Let dt  1 denote a consumer i’s purchase at time t. The first set focuses
on the persistence of purchasing any products on the market and are given by
Erdt 1  1|dt  1s  Prpdt 1  1|dt  1q
Erdt 2  1|dt  1s  Prpdt 2  1|dt  1q
Erdt 1  1, dt 2  1|dt  1s  Prpdt 1  1, dt 2  1|dt  1q. (3.6)
The remaining sets center on the persistence of purchasing products with character-
istic k. Now let dkt  1 denote a consumer i’s purchase at time t. The second set of
moments are given by
Erdkt 1  1|d
k
t  1s  Prpd
k
t 1  1|d
k
t  1q
Erdt 1  1, d
k
t 2  1|d
k
t  1s  Prpdt 1  1, d
k
t 2  1|d
k
t  1q
Erdkt 1  1, d
k
t 2  1|d
k
t  1s  Prpd
k
t 1  1, d
k
t 2  1|d
k
t  1q. (3.7)
The specific details for constructing these moments are provided in Appendix B.
Macro Moments
As discussed in Petrin (2002), the underlying approach in Berry et al. (1995) provides
two sets of aggregate moments. The first set of moments matches the shares in the
data, sj, to those predicted by the model, sjpδpθq, θq, and is given by
sjpδpθq, θq  sj  0 for j  0, 1, ..., J. (3.8)
Berry (1994) shows that this equivalence exists and is unique under mild regularity
conditions on the distribution of consumer tastes.
The second set of moments relates to market-level unobserved variation, ξjpθq.
We assume that this unobserved demand variation for any product is uncorrelated
with observed demand-side variables, with the exception of price. This means that
Erξjpθ0q|Xs  0. (3.9)
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Instruments for price are derived from the standard sources, as established by Berry
(1994).
The Objective Function
Both the macro moments, G1pθq, and micro moments, G2pθq, feed into the GMM
objective function. At θ0, these moment conditions are assumed to be uniquely equal
to zero, i.e.
ErGpθ0qs  E

G1pθ0q
G2pθ0q

 0. (3.10)
Hansen (1982) shows that the optimal (two-step) GMM estimator takes the form
θˆ  arg min
θPΘ
Gpθq1Gpθq, (3.11)
where Gpθq  apθ˜qGˆpθq, Gˆpθq is the sample analogue of Gpq, and apθ˜q is a consistent
estimate of the “square root” of the inverse of the asymptotic variance-covariance
matrix of the moments (obtained using θ˜, a preliminary consistent estimate of θ0).
3.3.4 Market Size and the Outside Good
To form our sample, we start by following the established path of defining daily dose
as a common basis of comparison to allow for estimation of substitutability between
products (Stern, 1996a; Berndt et al., 1997). These values are then scaled up to the
monthly level to correspond to the common duration of prescriptions. To construct
the size of the market and the share of the outside good, we assume the market
for H2 antagonists and PPIs is 20% of the total U.S. population, which is in the
range reported by Fedorak et al. (2010). Multiplying the U.S. population by the
20% prevalence gives the market size.
The market for antiulcer drugs also includes over-the-counter products that are
available without prescription. While this part of the market for H2s and PPIs
71
represents a small share of the market, it is still an important factor to consider.10
We account for changes in the over-the-counter market in two ways. First, we include
a dummy variable for whether a given molecule is also available in over-the-counter
form and interact this variable with generic status. This dummy enables us to include
competitive effects of the over-the-counter products to vary by brand/generic status
as well as to allow us to relax the assumption that when a PPI goes over-the-market
it affects all PPIs in the same way. Second, we include time dummies that are
interacted with the therapeutic drug class. This means that the over-the-counter
drugs can differentially affect each class, even though the effect on products within
each class may be more similar. Together, these steps allow us to more flexibly
account for the effects of over-the-counter products.
In estimating the demand, we consider both time-varying and time-invariant ef-
fects. We allow for time-varying product characteristics, Xjt, to enter the consumer’s
utility (any time-invariant characteristics will be subsumed by the product-specific
fixed effects). First, as described above, we allow for time dummies that vary by
class. This is important because consumer perceptions and over-the-counter offer-
ings may change over time. Additionally, we incorporate time-since-entry dummy
variables for each of the first twelve months after product entry, which may capture
product availability or aspects of consumer awareness. These dummies are allowed
to vary by therapeutic class. We also include cumulative log advertising at the
molecule-manufacturer-month level.11 As discussed in the data section, our measure
of advertising is detailing, which only occurs for branded products. All variants of
the same molecule are assumed to receive the same utility gain from advertising.
10 According to an analyst report, over-the-counter drugs accounted for a mean of 16% (standard
deviation of 2%) of the retail PPI market from 2009 through 2011 (BofA Merrill Lynch Global
Research using IMS Health prescription data and Nielsen over-the-counter data, April 2012).
11 In previous studies of the effect of detailing on demand for antiulcer drugs, the estimated
depreciation rate for the (detailing) advertising stock was zero percent (Berndt et al., 1995; Ling
et al., 2002; Ridley, 2014). Hence, we use the advertising stock with zero depreciation.
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This paper treats advertising as exogenous. Pharmaceutical manufacturers typically
lay out their advertising schedules far in advance and these schedules do not ap-
pear sensitive to monthly demand shocks that are commonly absorbed by the error
term. Finally, we include product-level fixed effects, where a product is defined at
the manufacturer-molecule-form level.
Identification
We use a panel of consumer-level data to generate average persistence of purchase
behavior across a number of product characteristics. This extra information allows
us to better estimate substitution patterns to reflect differences in taste for product
characteristics that are driven by demographics. In particular, by matching persis-
tence in choice, as it relates to observed product and consumer characteristics, we are
able to pin down individual heterogeneity parameters. Our choice of micro moments
is driven by the parameters we are seeking to identify.
3.4 Supply
In order to perform policy simulations, we need to impose a supply side model. This
then allows us to determine how producers react when uninsured consumers become
insured. Following the empirical industrial organization convention, we assume a
unique static, multi-product Bertrand Nash equilibrium in prices.
For each firm f at time t, let Jf index the firm’s portfolio of products. The
profits of firm f are then given by
Πf 
¸
jPJf
ppj mcjqMsjppq  aj  Cf , (3.12)
where sppq is the market share of product j, mcj is its marginal cost, M is the size
of the market, aj is the cost of advertising, and Cf is the fixed cost of production.
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Under our equilibrium assumption, the price, pj, and the implied marginal cost, xmcj,
must then satisfy the following first-order condition (FOC):
sjppq  
¸
rPJf
ppr  xmcrqBsrppq
Bpj
 0. (3.13)
The Jf equations in (3.13) can be used to calculate the price-cost margins for each
product. We define
Ωjrppq 
"
Bsrppq{Bpjt if Df : r, j P Jf
0 otherwise
(3.14)
and substitute it into the vector form of the FOC to get
sppq  Ωppqpp xmcq  0. (3.15)
Assuming Ωppq is non-singular, this equation can then be rearranged and used to
solve for the markups and implied marginal costs:
p xmc  Ωppq1sppq and xmc  p Ωppq1sppq. (3.16)
In addtion to providing marginal costs if they are not observed, this equation can be
used to simulate the equilibrium prices in our policy experiments.
3.5 Results
We start with the copay-price relationship defined in equation 3.4, the results of
which are presented in Table 3.2. As expected, we see a positive relationship between
copay and price; that is, more expensive drugs are assigned higher copays. Taking
into account the adjustments outline in Section 3.3.2, these parameters are used to
form copayments for the entire sample period.
The non-linear parameters, which capture the consumer types, are presented in
Table 3.3. Normalizing against the coefficients of consumers of type 1, we estimate
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for each of the other four consumer types the coefficients on dummies for having any
purchase (Buy), and purchasing a PPI (PPI), brand (Brand), and tablet formulation
(TAB). We also interact these dummies with an index of time (Time), which is
scaled down by 100. Finally, we report the probability of a consumer being each of
the specified types. These results indicate that most consumers are of type 3, who
do not buy often, but have a strong preference for generic PPIs in capsule form. The
second most prevalent group is consumers of type 5 and they buy a little more often
than consumers of type 3, but have a preference for branded PPIs. Consumers of
type 2 are similar to those of type 3, except they have a preference for the tablet
form that increases with time. Most of the estimates are significant, which validates
the approach of distinguishing between discrete consumer types.
Table 3.4 presents the results of selected linear parameters. As we would expect,
the price and advertising coefficients imply that consumers prefer products that
are lower priced and those that are advertised heavily, all else equal. For PPIs,
advertising has less of an impact, which may be due to consumers’ high awareness
of the availability of antiulcer drugs from the advertising on H2 products. This is
consistent with the results found in Arcidiacono et al. (2013). Interestingly, the time-
since-entry coefficients show no noticable trend in consumer purchases in the first 12
months.
3.5.1 Elasticities
We present the elasticities for own and cross-price effects in Tables 3.5 and 3.6 for
December 2005 and 2010, respectively. In these tables, price changes along each row
affect the market shares of the products in each column. We report the weighted
average elasticities across sales to insured and uninsured consumers for all branded
drugs as well as for the most popular generic version of each molecule. As expected,
uninsured consumers are consistently more price sensitive then their insured coun-
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terparts. This difference has important implications for the impact of extending
insurance to those consumers that are currently uninsured. Additionally, all own-
price elasticities are negative and greater than one in magnitude, which is consistent
with the economic theory. The cross-price effects are larger for products that have
larger market shares. However, given the form of our model, the effects from a price
change of a given product are mostly independent of the characteristics of any other
product. Notably, the PPIs are closest substitutes to other PPIs, as one might ex-
pect. On the other hand, H2s are more likely to lose share to a PPI, as opposed to
another H2.
3.5.2 Marginal Costs
Once we have our demand estimates, we can use the supply-side model and as-
sumptions to calculate the implied marginal costs. In Figure 3.5, we present these
results for the two most recent products to experience generic entry within our sam-
ple period. The vertical dashed lines indicate the timing of the initial generic entry.
Interestingly, there is little to no response to generic entry on both lansoprazole and
pantoprazole. These findings deviate from much of the prior literature that uses
models with a logit error.
3.6 Conclusion
Using data from the pharmaceutical industry, we estimate demand and supply for
prescription drugs across both insured and uninsured consumers, allowing for con-
sumer preferences organized into discrete types. We account for an important char-
acteristic of health care markets: the price paid by insured consumers (copayment)
is typically much smaller than the price received by the manufacturer. Our anal-
ysis highlights how generic-drug availability differentially affects insured and unin-
sured consumers. In particular, generic entry disproportionately benefits insured
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consumers, at least in the first year to two years.
The estimates from our models of demand and supply allow for the examination
of policy experiments. Among the potential experiments is examining the welfare
impact of the insurance expansion under the Affordable Care Act (ACA or “Oba-
macare”), as it impacts consumers, producers, and insurers. Insurance expansion
creates possible spillovers for manufacturers. In ongoing work, we will estimate the
increase in profit, isolating the price effect from the quantity effect. Additionally, we
will do a back-of-the-envelope calculation in which we compare the profit increase
associated with the ACA to the tax imposed on manufacturers to help pay for the
insurance expansion. Congress anticipated the profit windfall pharmaceutical man-
ufacturers would gain from the expansion of insurance under the ACA and created
a tax on pharmaceuticals (to help pay for the insurance expansion). Section 9008 of
the Affordable Care Act set forth the Branded Prescription Drug Fee Program. The
government sums sales to the government (Medicare, Medicaid, military, veterans)
and then taxes manufacturers on this basis.12 The ten-year cost to manufacturers is
expected to be $30 billion.13
12 http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-
Topics/Benefits/Prescription-Drugs/Branded-Prescription-Drug.html
13 http://www.forbes.com/sites/brucejapsen/2013/05/25/obamacare-will-bring-drug-industry-35-
billion-in-profits/
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Table 3.1: Market Entry by Molecule
Brand Brand OTC 1st Gen Gen List of
Class Molecule Name Entry Entry Entry Entrants Forms:
cimetidine Tagamet Aug-77 Aug-95 May-94 36 Tab
H2
ranitidine Zantac Jul-83 Apr-96 Jul-97 32 Tab, Cap
famotidine Pepcid Nov-86 Jun-95 Apr-01 19 Tab
nizatidine Axid May-88 Jul-96 Jul-02 9 Cap
omeprazole Prilosec Oct-89 Sep-03 Nov-02 12 Cap
lansoprazole Prevacid May-95 Nov-09 Nov-09 4 Cap, Tab
rabeprazole Aciphex Sep-99 - - - Tab
PPI pantoprazole Protonix Apr-00 - Dec-07 4 Tab
esomeprazole Nexium Feb-01 - - - Cap
omeprazole NaHCO3 Zegerid Oct-04 Mar-10 Jul-10 2 Cap
dexlansoprazole Dexilant Feb-09 - - - Cap
: Forms are listed in order of popularity.
Table 3.2: Regression results. Dependent variable is Ln(copayment)
Coefficient Standard Error
Constant 2.558 (0.279)
Ln(price) 0.113 (0.056)
N=100. Observations are at the insurance group-molecule-month level.
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Figure 3.3: Retail Prices and Copayments for Branded and Generic H2 Drugs.
81
 $‐
 $20
 $40
 $60
 $80
 $100
 $120
 $140
 $160
 $180
 $200
Brand Price Generic Price Brand Copay Generic Copay
$ for 30‐day Supply
(a) omeprazole
 $‐
 $20
 $40
 $60
 $80
 $100
 $120
 $140
 $160
 $180
 $200
Brand Price Generic Price Brand Copay Generic Copay
$ for 30‐day Supply
(b) lansoprazole
$0
$20
$40
$60
$80
$100
$120
$140
$160
$180
$200
Brand Price Generic Price Brand Copay Generic Copay
$ for 30‐day Supply
(c) rabeprazole
$0
$20
$40
$60
$80
$100
$120
$140
$160
$180
$200
Brand Price Generic Price Brand Copay Generic Copay
$ for 30‐day Supply
(d) pantoprazole
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Table 3.4: Linear Parameters
Interaction with PPI
Coefficient Standard Errors Coefficient Standard Errors
Copay -0.5179 (0.1431)
Own-Molecule OTC -0.9037 (3.0866)
Brand x Own-Molecule OTC -7.6415 (3.0205)
Insured -27.3797 (7.8701)
Insured x Generic 12.9805 (3.5871)
Brand x generic competition -2.3346 (1.1860) -5.3412 (3.6789)
Ln Cumulative Advertising 15.7669 (6.4262) -10.5903 (5.6963)
1 month on market 0.2394 (1.4018) 1.2539 (2.347 )
2 month 1.7433 (1.4945) 1.5980 (2.2507)
3 month 1.2599 (1.3156) 3.0780 (2.3119)
4 month 1.2433 (1.2819) 3.5177 (2.4054)
5 month 1.4406 (1.2818) 3.1143 (2.3962)
6 month 1.5529 (1.2691) 2.8323 (2.3771)
7 month 1.5754 (1.2529) 3.3596 (2.4690)
8 month 1.5056 (1.2339) 2.9270 (2.4360)
9 month 1.4812 (1.2140) 2.6891 (2.4240)
10 month 1.3663 (1.1925) 2.8399 (2.4399)
11 month 1.2535 (1.1708) 3.3848 (2.5004)
12 month 1.3214 (1.1714) 3.1762 (2.4805)
N=15749. Estimated jointly with non-linear parameters. Also includes manufacturer-molecule-form
fixed effects, month dummies, and month dummies cross PPI. There are 600 linear parameters.
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4Patent Breadth versus Length with High-Value
Followers
4.1 Introduction
Patent policy maximizes social welfare by promoting the creation of valuable inno-
vations and limiting the costs that stem from market distortions and duplicative
spending. The standard levers of these policies are patent breadth, which restricts
competitive imitation (the scope of protection), and patent length, which specifies
the amount of time the protection can be enforced. The first empirical assessment of
the trade-off between these levers is provided in Chapter 2, which uses data from the
U.S. pharmaceutical industry to show that under certain conditions social welfare
can be improved.1 In this chapter, I ease one of the main assumptions made in that
analysis to allow for a more generalized framework and determine if the results still
hold.
In order to make this problem more tractable, Chapter 2 highlights features of
the pharmaceutical industry and relies on a number of assumptions. In particular,
product innovations in this industry are exogenously categorized based on their target
1 Chapter 2 corresponds to Taylor (2014).
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in the body (mechanism of action). Products in the same category, called therapeutic
class, are therefore very similar in their use and benefits. Chapter 2 examines the
impact of expanding patent breadth from the chemical composition (molecule) level
to the therapeutic class level. To simplify the analysis, that chapter assumes that
while the first innovation in a class is a high-value product, all that follow are “me-
too” drugs that provide relatively little, if any, added therapeutic value to the market
beyond the first. However, this is often not the case. A notably relevant example
is Lipitor, which was the sixth innovation to enter the therapeutic class of statins
(cholesterol drugs), but is the best-selling drug of all time. The highly successful drug
Zoloft provides another example as the second antidepressant to target the serotonin
reuptake mechanism in the body. In this chapter, I ask the following question: Do
the results from Chapter 2 still hold when an innovation that is not first-in-class is
considered to be high-value and provided with the modified patent?
As a simple motivating example, consider a market with two product innovations
and suppose both are high value, i.e. the second provides major therapeutic value
to consumers beyond the first. Under the assumption in Chapter 2, only the first
innovation would receive the modified patent, while the second would be delayed
from entering the market. However, this would mean that consumers would suffer
a significant loss in this delay, which could potentially last a number of years. Now
suppose that the remaining patent life on the second innovation after the delay is too
short to allow the innovator to make sufficient profit on its investment in the third
phase of clinical trials. In this setting, the innovator would choose to abandon the
innovation and retain this investment. In turn, this would mean the permanent loss
for consumers of the brand product as well as the generics that would have followed.
The net impact of this scenario could result in a large social welfare loss. For this
reason, it is important to ease the restriction in Chapter 2 and allow for the potential
that later innovations into the market are high value.
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I use estimates from the static model of demand presented in Chapter 2 in or-
der to implement the analysis in this chapter. The model allows for the quality of
products to be determined by consumer preferences. It is then assumed in the policy
experiments which products are high-value innovations and which are “me-too”s.
The first policy experiment modifies the patent of all high-value innovations to limit
the profit, and therefore the incentives to develop “me-too” drugs. Specifically, I
expand the patent breadth and limit the patent length of the high-value antidepres-
sants, Prozac and Zoloft, in order to temporarily restrict the subsequent “me-too”
products in the same therapeutic class from entering the market. I find that the
patent lives of Prozac and Zoloft are shortened by 26 months and 52 months, re-
spectively. Additionally, the $1.4 billion in lost profits (49.8%) suffered by “me-too”
innovators is overshadowed by the $8.3 billion in savings (11.3%) realized by insur-
ers. Finally, consumers experience a welfare gain of $166 million (0.8%) under the
modified framework. The total social impact of this modified policy is a gain of more
than $9.1 billion (7.9%).
The second counterfactual builds on the first, by allowing the “me-too” innova-
tors to anticipate the impact of the modified policy on their expected profits and
reoptimize their entry decisions during their respective drug development processes.
Those innovators that abandoned their drugs save their remaining investment expen-
ditures. I find that while Lexapro would always proceed through Phase III clinical
trials and onto the market, Paxil and Celexa would do so with probabilities of only
18.1% and 5.8%, respectively. The net effect on producers is a gain of $1.1 billion
(5.0%) due to the expenditures saved by entry re-optimization. In cases where the
products do not enter the market, consumers lose the value of their entry as well as
the generics that would have followed on each molecule. Diverging from the results
in Chapter 2, this effect is larger than the benefit that consumers gain from earlier
generic entry on the molecules for both Prozac (fluoxetine) and Zoloft (sertraline),
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and leads to a consumer loss of $84 million (0.4%). However, insurers still realize
large gains ($8.3 billion or 11.3%) as consumers who would have otherwise purchased
Paxil and Celexa, turn to generic fluoxetine and sertraline instead. The net social
welfare effect sums to $9.3 billion (8.1%). These results indicate the potential for
meaningful social gains from exploring modified patent policies in a more realistic
setting.
While this work extends the study of the tradeoff between patent breadth and
length, some aspects of the problem are still not addressed. For example, this chapter
does not try to address the question of how much the initial innovators should be
rewarded; instead, like most of the theory literature, it considers how to give the
initial innovator a fixed reward. Additionally, the analysis includes only a limited
range of dynamics. While “me-too” innovators are allowed to reoptimize their entry
decisions, the decisions of other market participants are assumed to be exogenous
and held fixed. At the end of the chapter, I discuss ongoing work that seeks to
address this last limitation.
I proceed in the chapter by first providing some background to highlight im-
portant features of the market that are relevant for this analysis.2 In Section III,
I implement the counterfactual simulations to measure the welfare implications on
consumers, insurers, and producers (innovators and manufacturers). Finally, Section
IV concludes.
4.2 Background
In this section, I provide some brief background information relevant to the market
that allow me to implement the policy experiments. A full description of the industry
and data are provided in Chapter 2.
2 Readers should refer to that Chapter 2 for a review of the related literature and a full description
of the industry, data, and the model of demand and supply with the corresponding results.
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The antidepressant market is dominated by two therapeutic classes. The first
class is often referred to as Other Antidepressants or as New Generation Antide-
pressants (NGAs) and these products appear to allow for increased levels of nore-
pinephrine and dopamine in the brain. On the other hand, the second and more
prominent of the two classes consists of selective serotonin reuptake inhibitors (SS-
RIs), which elevate only serotonin in the brain. Nearly all of the antidepressant
products sold under patent between 1991 and 2010 belong to either the SSRIs or
NGAs. Table 4.1 provides details on the top selling products in each class, including
launch and patent expiration dates.
As shown in Figure 4.1, SSRIs sales were dominated by Prozac and Zoloft. The
SSRIs began in 1988 with the market introduction of Prozac, which immediately
became the most prevalent product in the market with annual sales of over $1 billion.
Following on Prozacs success, Zoloft was released in early 1992 and successfully
competed for sales. Paxil entered the market in the beginning of 1993 and Celexa,
in the second half of 1998, but neither attained the same success. Finally, Lexapro
entered the market in the second half of 2002 and achieved greater success than either
Paxil or Celexa, despite its entry into the market after Prozac’s patent expired.
Zoloft’s success during this period may be due to a number of reasons including
valuable therapeutic differences, pricing, and marketing. For example, Prozac and
Paxil have a higher risk of some drug interactions than does Zoloft (Spina and Scordo,
2002). In the analysis that follows, I treat both Prozac and Zoloft as high-value
innovations, while the subsequent entrants are assumed to be “me-too”s.
4.3 Modified Policies
This section provides a framework that measures the welfare implications of modify-
ing patent breadth and length, which is then applied to the pharmaceutical industry.
My analysis is informed by features of the market as well as estimates of consumers’
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substitution behavior that come from the demand model presented in Chapter 2.
As noted above, this model allows for the quality of products to be determined by
consumer preferences. In the policy experiments, I then assume that Prozac and
Zoloft are high value innovations and the later innovations are “me-too”s.
4.3.1 Overview
The abstract search for an optimal patent policy is limited to what is feasible for
a given market. Any analysis that searches for an optimal patent policy requires that
the measure of patent breadth be defined in such a way that is known to the market
and independent of any decisions made by the firms. For the pharmaceutical industry,
there are three such feasible levels for breadth. The narrowest is the molecule level,
which is the breadth specified under the existing policy. The other two are the
therapeutic class level and the entire market. I expand breadth to the therapeutic
class and then scale the patent length in order to make the high-value innovator
indifferent between the two policies.3
For my policy experiments, I model patent breadth on the high-value innovation
as the degree to which it can restrict “me-too” products from entering the market,
but not other high-value innovations that may follow.4 The “me-too” innovators that
are restricted from the market retain ownership of their patents under the modified
policy.5 The implication of this is that once the patent on the high-value product
expires or a second high-value product enters the market, the “me-too” products
3 This follows the conceptual framework in much of the prior literature.
4 As discussed in Section 2.3.1, the temporal disconnect between when an innovation is patented
and when its value is known implies that the conventional framework of patent policy is not well
suited for examining alternative levels of patent breadth and length.
5 While I ignore the possibility that a drug may be used for multiple completely different markets
(treatments), it is a simple matter to focus the entry restriction to only a specified market and still
allow access in other markets. For example, the popular hair treatment Rogaine (minoxidil) is also
used to treat high blood pressure (under the trade name Loniten). Even if it had temporarily been
blocked as a high blood pressure medication, as the first hair growth drug approved by the FDA,
it would be free to enter this second market.
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that were delayed by the first high-value product can then enter the market.
For the purpose of exposition, Figure 4.2 depicts the profit over time for multiple
high-value innovations, m0 and m2, as well as multiple “me-too” innovations, m1 and
m3. By design, m2 provides significant added therapeutic value beyond m0, while m1
and m3 are “me-too”s of m0 and m2, respectively. Upon their entry, the “me-too”
products negatively impact the profit of the high-value products. I propose a policy
modification whereby the patent breadth of m0 is increased so as to delay the market
entry of m1, but not m2. The entry of m2 transfers the expanded patent breadth
from m0 to m2, which allows m1 to enter the market and delays the entry of m3. The
patent lives of m0 and m2 are each limited to ensure at least the same net present
discounted profit earned under patent protection, V f . This means that the delay of
m2’s entry onto the market also affects the patent length of m0. Figure 4.3 illustrates
the shift in the timing of market entry for each market participant. The reduction
in the patent lives of m0 and m2 are shown as the shift from the light dotted lines
to the dark dashed lines. In practice, the net present discounted profit for m0 and
m2 under patent protection may be greater than V
f if time is treated as a discrete
measure. The market entry of m1 is delayed until the entry of m2, while the entry
of m3 is delayed until m2’s shorter patent expires.
I focus my analysis on the market for antidepressants, in which Prozac was the
first SSRI and was clearly a high-value innovation. I then assume that Zoloft provides
significant therapeutic value beyond Prozac, while the three SSRI molecules that en-
ter the market after Zoloft are “me-too”s.6 While Paxil CR also entered the market
during this time, it represents an advancement over Paxil in the formulation and not
the molecule. For this reason, I combine Paxil and Paxil CR as one innovation in the
policy experiments. Given that Zoloft was the first SSRI to follow Prozac, I extend
6 Currently, there is no formal definition or explicit quality thresholds that distinguish high-value
and “me-too” innovations.
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Zoloft’s patent breadth to the therapeutic class level and temporarily exclude these
“me-too” innovations. However, Prozac’s patent length is still limited so that its in-
novator earns the same net-present discounted profits under patent protection. This
restriction only applies to later entrants in the SSRI class and therefore, innovations
in other classes would not be directly affected.
Below, I present two counterfactuals and compare their results to those in Chapter
2. The first assumes that all “me-too” innovations that entered under the original
policy also enter under the modified policy, once Prozac’s shortened patent length
expires. For the second counterfactual, I provide a framework which allows “me-
too” innovators to anticipate the impact of the modified policy and re-optimize their
entry decision before entering Phase III clinical trials. Innovators that choose to forgo
additional drug development and eventual market entry would save the associated
investment costs.
4.3.2 Exogenous Entry
Social Welfare under Exogenous Entry
The net discounted social welfare impact of the modified policy is the sum of the
discounted effects on consumers (CV ), insurers (Πins), and producers (Πdiff ).7 This
is given by
SC  CV   Πins   Πdiff . (4.1)
I assume that consumers and insurers have an annual discount rate of 5% while the
producers’ discount rate is 11%, which accounts for the innovator’s risk of product
failure during the product development process (DiMasi et al., 2003). The use of
this higher producer discount rate means that, for a given amount of patent breadth,
the innovator of the groundbreaking drug will require relatively less patent length in
order to realize V f . Under exogenous entry, consumers benefit from this shortened
7 Producers include both innovators and manufacturers.
95
patent length due to the expedited entry of the generics on Prozac’s molecule.8 The
implications for the “me-too” innovators is less clear. While they are able to enter
the market sooner under the higher discount rate, they also place greater value on
the time they are restricted from the market. However, I find that the final results
are not qualitatively different when I use a 5% discount rate for producers.
As previously noted, prescription drug costs comprise only a small fraction of
household income. Thus, I use compensating variation to calculate the impact that
switching to the modified patent policy will have on consumers. Interestingly, this
impact can be fully captured by the difference in log shares of the outside good under
the two policies, magnified by the size of the market and translated into dollars by
the disutility of price (copay) (Arcidiacono and Miller, 2011). For all consumers at
time t, this is given by
CVt  
Mt
α

ln
 
sante0t

 ln
 
spost0t

(4.2)
where sante0t and s
post
0t denote the share of the outside good at time t under the current
and modified policies, respectively. The total discounted welfare change is then
CV 
T¸
t1
CVt  p1  d
cqt1 (4.3)
where dc is the rate at which consumers discount utility.
While consumers pay only a fraction of the full drug prices, the rest of the price
is paid by insurers. Therefore, insurer savings from the switch to the modified policy
is given by
Πins 
T¸
t1
#
J¸
j1

ppantejt  c
ante
jt qs
ante
jt  pp
post
jt  c
post
jt qs
post
jt

Mt  p1  d
cqt1
+
, (4.4)
8 In the case of endogenous entry, consumer welfare will depend on the choices made by the
“me-too” innovators.
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where the terms identified as ante and post correspond to the equilibrium prices
and shares under the current and modified policies, respectively. Note that the
insurers, like the consumers, are payers and so their expenditures are discounted by
the consumer rate, dc.
The profit of firm f at time t is
Πft 
¸
mPJft
¸
jPm
rppjt mcjtqMtsjpptqs  amt  Cft (4.5)
where amt is the cost of advertising, Cft is the fixed cost of production, and sjpptq is
the market share of product j and is a function of the prices of all products at time
t. For the producers’ net total welfare effect (innovators and generic manufacturers),
the difference of each producer’s profit under the current and modified policies is
summed across all producers and discounted to time t  1. That is,
Πdiff 
T¸
t1

F¸
f1
 
Πpostft  Π
ante
ft

 p1  df qt1
ff
, (4.6)
where df is the rate at which producers discount profits, and Πanteft and Π
post
ft are
producer f ’s profit under the current and modified policies, respectively.
For simplicity in implementing the simulations of the modified patent policies,
I use the averages over time of both implied marginal cost, mcj, and unobserved
product heterogeneity, ξj, for each product j.
Results under Exogenous Entry
The first SSRI, Prozac, entered the antidepressant market in January 1988 and
enjoyed an effective patent life of 13.5 years. Following Prozac, Zoloft emerged
onto the market in February 1992 and its patent lasted 14.4years. During its patent-
protected time on market, three other SSRI drugs entered the market: Paxil, Celexa,
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and Lexapro.9 I assume that these are “me-too” drugs, and restrict them from the
market until Zoloft’s patent expires under the modified policy. Under the original
policy, I then calculate the present discounted profits generated by both Prozac and
Zoloft while under patent protection. This amount is then set as the minimum profit
requirement for each innovation under the modified policy. Given the restriction
under the modified policy, I find that Zoloft’s innovator is able to earn at least the
same present discounted profits with a patent that expires in April 2002, reducing
its patent life by 52 months (30%).10 The delay of Paxil and Celexa also benefit the
innovator of Prozac. To provide its innovator with approximately the same present
discounted profits, Prozac’s patent life is reduced by 26 months (21%).
Table 4.2 provides the impact of the policy switch on the “me-too”s. The effective
patent life for Paxil and Celexa are shortened by 9.18 and 3.58 years, respectively. For
Paxil, this is a reduction of nearly 90% of its patent protected time on market, while it
is almost 60% for Celexa. On the other hand, Lexapro entered the market in August
2005 and so its effective patent life is unaffected. Once on the market, the “me-
too” drugs compete against Prozac (fluoxetine), Zoloft (sertraline) and their generic
variants. Discounted to January 1991, Paxil experienced a $930 million loss in profit
(91% reduction) due to its delayed entry and competition against generic fluoxetine
and sertraline. For Celexa, this loss was only $414 million, but this amounts to
more than 96% of its profit under the original policy. The impact on Lexapro is
exclusively from its competition with generic sertraline. The last row in Table 4.2
shows the impact of the generic versions of each of these “me-too” drugs. Under
the orginal policy, generics on both Paxil (paroxetine) and Celexa (citalopram) enter
before those on sertraline. The earlier entry by generics on sertraline results in a
9 As previously stated, Paxil CR represents an advancement over Paxil in the formulation and
not the molecule. For this reason, I combine Paxil and Paxil CR as one innovation in the policy
experiments.
10 Note that time in my data is in increments of months.
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non-trivial impact on profits earned by generics on these subsequent molecules.
The total effect for each segment of the market is provided by Table 4.3. Under
the counterfactual simulation, Prozac earned an additional $21 million and Zoloft
earned an additional $6 million, primarily due to the discreteness of time in setting
their new patent lengths. The impact of the policy switch generated more than $1.3
billion and $900 million in additional profits for producers of generic fluoxetine and
sertraline, respectively. Note that I assume that the number and relative timing
of entry among the generic fluoxetine and sertraline producers remains the same.
The overall timing is simply advanced to the new patent expiration date for both
molecules.11 The total impact for “me-too” brands and generics are simply the totals
of the figures in Table 4.2. As expected, the impact on the rest of the products in the
market is fairly small. The net impact across all producers is a gain of nearly $700
million. Allowing additional generic entry on fluoxetine and sertraline would then
reduce their super-normal profits and lead to a large and negative net impact across
all producers. However, this potential negative impact on producers is overshadowed
by the substantial savings by insurers, more than $8.2 billion (an 11.3% reduction
in expenditures). This stems from the substantially lower cost to insurers when
consumers purchase generics over brand name products and with the advanced timing
of generic entry on both Prozac and Zoloft. Finally, consumers realize a small net
gain due to this advanced timing of generic entry, despite the broadening of Zoloft’s
market exclusivity to temporarily restrict the entry of “me-too”s. The overall effect
on social welfare is a $9.1 billion gain. While this net welfare result is smaller than
the corresponding number reported in Chapter 2, the overall implications remain the
same.
11 For example, consider two generic firms, A and B, where Firm A enters two months before Firm
B. Under the counterfactual, Firm A will still enter two months before Firm B, even though overall
both enter the market earlier.
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The above policy experiment examines the impact of allowing next-in-class prod-
ucts to be considered high-value innovations and receive the modified combination of
patent breadth and length. However, it maintains the same entry decisions for sub-
sequent entrants that are defined as “me-too”s. For the second policy experiment,
I relax this assumption on the entry decisions by “me-too” innovators to provide a
more robust approach to estimate the social welfare impact.
4.3.3 Endogenous Entry
Entry Re-optimization
I now consider the impact of allowing “me-too” innovators to anticipate the impact
of the modified patent policy on their expected profits and re-optimize their decision
to enter Phase III clinical trials.12 I implement this by focusing on innovators that
were observed to enter the market under the current policy and comparing their
entry costs to their expected profits. Hence, an innovator will save its investment
costs of Phase III if it chooses not to continue. For simplicity, I assume that entry
of previously unseen products does not occur under the modified policy. Under
the current policy, innovators enter in a sequential order f 1, ..., fn and then realize
profits Π1,ante, ...,Πn,ante, respectively. It is also assumed that this order reflects the
order in which innovators reach their decision point at the end of Phase II clinical
trials. Finally, I assume a full information game where innovators see the product
qualities, development costs, and time to market entry of all the other potential
market entrants. Therefore, innovator f can anticipate the impact of the modified
policy on the timing of when product j would be allowed to enter the market.
Let Cfj be innovator f ’s fixed Phase III clinical trial costs for product j and
assume Cfj  FNpµ, σ2|0 ¤ κ   Cfj   V antefj q, where Cfj is independent across
12 By the end of Phase II clinical trials, innovators have usually gained their first significant evidence
of efficacy and safety (DiMasi et al., 1991; Mossinghoff, 1999). I assume that this is sufficient to
make an informed decision.
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innovators and products, V antefj is innovator f ’s net present discounted profit from
product j under the current policy, κ is a lower bound on costs, and FN is a truncated
normal distribution:
FN 
Φp
Cfjµ
σ
q  Φpκµ
σ
q
Φp
V antefj µ
σ
q  Φpκµ
σ
q
. (4.7)
Innovator f will choose to send product j to Phase III clinical trials under the
modified policy if Cfj   V
post
fj , where V
post
fj is innovator f ’s net present discounted
profit from product j under the modified policy.13
In order to estimate the probability of each possible market outcome under the
modified policy, I apply the following simple algorithm:
1. Draw Cfj for each product.
2. Determine the re-optimized decision for each product using backward
induction.
3. Repeat Steps 1 and 2 N times.
4. Finally, calculate λn, the probability of each possible market outcome,
n  1, ..., N .
When simulating the entry re-optimization, I use estimates (in December 2010
dollars) calculated by DiMasi et al. (2003) for average Phase III costs, µ  $143
million, and standard deviations, σ  $118 million, for approved drugs. DiMasi
et al. (2003) also estimated that the average length of time from the start of Phase
III to drug approval is 52 months. I use this estimate to calculate Vfj for innovator
f and product j. Finally, I set κ to be $1 million.
13 Given that these products were approved by the FDA under the current policy, they would still
be approved under the modified policy. The question is merely one of timing if products continue
on to Phase III.
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Social Welfare under Endogenous Entry
The social welfare calculation under endogenous entry is a simple analog of the
exogenous case that includes probability weights for the N market outcomes. The
equations corresponding to (4.2)-(4.6) for the counterfactual with endogenous entry
for “me-too” are given by:
CVt,n  
Mt
α

ln
 
sante0t

 ln
 
spost0tn

, (4.8)
CV 
N¸
n1
λn

T¸
t1
CVt,n  p1  d
cqt1
ff
, (4.9)
Πins 
N¸
n1
λn

T¸
t1
#
J¸
j1
 
pantejt  c
ante
jt

santejt 
 
ppostjtn  c
post
jtn

spostjtn

Mt  p1  d
cqt1
+
,
(4.10)
and Πdiff 
N¸
n1
λn
#
T¸
t1

F¸
f1
 
Πpostftn  Π
ante
ft

 p1  df qt1
ff+
. (4.11)
Let IPhaseIIIjn be the expenditure saved when innovation j is abandoned rather than
taken to Phase III clinical trials, discounted to time t  1 using the rate df . The
total expenditure saved across all such abandoned innovations is given by
IPhaseIII 
N¸
n1
λn

J¸
j1
IPhaseIIIjn

. (4.12)
Finally, the discounted social welfare effect is then given by
SC  CV   Πins   Πdiff   IPhaseIII . (4.13)
Results under Endogenous Entry
As before, the “me-too” drugs may enter the market starting in April 2002. The
lower and upper bound values that plugged into the truncated normal distribution
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in equation (4.7) are provided in the first two rows of Table 4.4. To calculate the
upper bound, the net present profit of each product is discounted back to the start of
Phase III clinical trials. This is assumed to be 52 months prior to the orginal market
entry date for all products. Note that all of the products have an upper bound that
is substantially higher than the distribution mean of $143 million. The middle two
rows of Table 4.4 give the average and standard deviation of draws from step (1) of
the algorithm. Given that the “me-too” innovators make their decisions in sequential
order, backward induction is used to determine the market outcome for each set of
cost draws. The probability of entry for each drug is provided in the fifth row of the
table. Lexapro will always go into Phase III clinical trials and eventually enter the
market, while Paxil and Celexa will do so 18% and 6% of the time, respectively. The
last row in the table provides the saved expenditure weighted by market outcome.
The impact of the policy switch on the “me-too”s is provided in Table 4.5. The
first row of Table 4.2 matches the results in the first row here. Given the “me-
too”s ability to reoptimize their entry decision, it is intuitive to expected that profit
loss for the “me-too” brands would be lower. Summing the saved expenditure and
the change in product profit easily confirms this expectation. The impact on the
“me-too” generics is more closely tied to the entry decisions by the corresponding
innovators. Generic entry on that molecule is assumed to never occur if a brand
product is abandoned by its innovator. Lexapro is shown to benefit considerably
from the low entry probability of both Paxil and Celexa. My data does not capture
generic entry on Lexapro’s molecule.
The net welfare effect for each segment of the market is presented in Table 4.6.
The impact on generic versions of Prozac and Zoloft is now larger due to the limited
competition when the other “me-too” products are abandoned. The seventh row of
the table shows that the other products on the market also enjoy this benefit, though
to a much smaller degree. Overall, the producers gain a profit of nearly $840 million.
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By abandoning their products prior to Phase III, these innovators also saved $288
million in corresponding expenditures. The welfare of both insurers and consumers
decreases, mostly due to the near certain loss of both paroxetine and citalopram.
However, the overall effect is a social welfare gain of $9.3 billion, which is larger than
the modified policy with exogenous entry.
4.4 Conclusion
This chapter extends the analysis in Chapter 2 to allow for a more generalized frame-
work. In that chapter, the first pharmaceutical product innovation that enters a
therapeutic class is assumed to be high-value while those innovations that follow are
assumed to provide relatively little, if any, added therapeutic value beyond the first.
Using the same data and demand model estimates, I consider the potential welfare
effects of allowing these later to be considered high-value products and providing
them with greater patent breadth and shorter patent length. In this chapter, I show
that the results presented in Chapter 2 are robust to adjustment in the modified
policy framework.
However, how innovations are determined to be either high quality or “me-too”
innovations and the way in which they are treated once this determination is made
are important issues. Currently, there is no definition or explicit quality thresholds
to distinguish between high-value and “me-too” innovations. It is therefore necessary
to rely on ad hoc assumptions to specify these thresholds. If high value innovations
are not identified as such, there is a potential for significant welfare loss, which may
also have a negative impact on the long-run innovation flow. On the other hand, if
the assumption sufficiently covers all innovations that are truly high value, there is
relatively little concern about the potential of misidentifying a “me-too” as a high
value product. The reason for this stems from that fact that if all products are
assumed to be high value, this modified patent is never applied and we are simply
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left with our current policy.
The results in this chapter further support the potential for meaningful social
gains from exploring modified patent policies. However, my analysis still relies on a
variety of assumptions that simplify the problem, but also limit the generalizability of
my conclusions. For example, I still abstract away from any uncertainty consumers
may have of the quality of new products introductions. If consumers learn about
this quality from each other, then the higher counterfactual price on Prozac would
induce more price-sensitive consumers to switch to generic versions. In turn, this
would speed up consumers’ learning process as well as the adoption rate of these
generics. Therefore, the modified patent policy could potentially further increase
the competitive pressure on Prozac’s innovator after patent expiration. It is left for
future work to examine the effects of relaxing this and other assumptions, including
those restricting the dynamic behavior of insurers and other market participants.
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Figure 4.1: Area Plot of Monthly Quatity Sales for the Top SSRI Molecules with
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Figure 4.2: Demonstrative for Current Patent Policy
106
m2
* patent 
expiration 
m1
* 
m2
* 
T2 
m3
* 
T3 T2
* T0
* 
m0** 
Profit ($) 
T0 
m0* patent 
expiration 
m1 patent 
expiration 
T1 
m3 patent 
expiration 
Figure 4.3: Demonstrative for Modified Patent Policy
Table 4.1: Drug Details
Drug 1st 1st 1st Number of
Class Moleculea Brandname Launch Patent Exp.b Genericsc
NGA bupropion Wellbutrin 1986m3 1999m12 8
NGA venlafaxine Effexor 1994m2 2006m8 14
NGA nefazodone Serzone 1995m1 2003m9 7
NGA mirtazapine Remeron 1996m7 2003m1 11
NGA duloxetine Cymbalta 2004m8 – –
SSRI fluoxetine Prozac 1988m1 2001m7 18
SSRI sertraline Zoloft 1992m2 2006m6 17
SSRI paroxetine Paxil 1993m1 2003m5 9
SSRI citalopram Celexa 1998m8 2004m10 17
SSRI escitalopram/oxalate Lexapro 2002m8 – –
Source: SDI Database.
a Selected sample of the top selling antidepressants.
b First patent expiration values are missing if the patents are still active on December
2010.
c Generics refers to the number of generic producers that compete under a given
molecule.
Table 4.2: Impact of Modified Policy on “Me-Too” Drugs with Exogenous
Entry
Change in Levels Percentage Change
Change in: Paxil Celexa Lexapro Paxil Celexa Lexapro
effective patent lifea -9.17 3.58 0 88.0% 58.1% 0.0%
PV(brand profit)b -930 -414 -98 -91.2% -96.0% -6.8%
PV(generic profit)b -39 -14 0 -8.4% -5.3% 0%
a Effective patent life is in years.
b All dollars are in millions and discounted to January 1991 with a rate of 11%.
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Table 4.3: Present Value Welfare Under Ex-
ogenous Entry
Change In Dollarsa % Change
Prozac profitb 21 0.8%
generic Prozac profitb 1304 88.8%
Zoloft profitb 6 0.1%
generic Zoloft profitb 952 206.2%
‘me-too’ brand profitb -1442 -49.8%
‘me-too’ generic profitb -53 -7.3%
other non-SSRI profitb -99 -1.1%
all firms’ profitb 689 3.1%
insurer savingsc 8291 -11.3%
consumer welfarec 166 0.8%
social welfare 9146 7.9%
a Dollars are in millions and discounted to January 1991.
b Firms’ profits are discounted at 11%.
c Insurer savings and consumer welfare are discounted at
5%.
Table 4.4: Distribution Bounds and
Average Costs of Phase III Clinical
Trialsa
Paxil Celexa Lexapro
lower boundb 1 1 1
upper boundb 776 630 3363
mean(cost)c 169 171 168
sd(cost)c 98 99 98
Prob(entry)c 18.1% 5.8% 100%
IPhaseIII 178 110 –
a All dollar values are in millions.
b Lower and upper bounds of the products’ re-
spective truncated normal distributions. The
upper bounds are calculated as the net present
value profit of each product, discounted to the
start of Phase III clinical trials, 52 months prior
to market entry.
c Based on 10,000 random draws for each product.
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Table 4.5: Impact of Modified Policy by Moleculea
Change in Levels Percentage Change
Change in: Paxil Celexa Lexapro Paxil Celexa Lexapro
effective patent lifea -9.17 3.58 0 88.0% 58.1% 0.0%
PV(brand profit)c -1002 -430 184 -98.3% -99.7% 12.7%
PV(generic profit)c -379 -247 0 -81.9% -93.9% 0%
a Effective patent life is in years.
b Phase III clinical trial costs are weighted by entry decisions and then discounted or inflated
to January 1991.
c Profits are calculated according to equation (4.11), then weighted by entry decisions and
discounted to January 1991. All dollars are in millions.
Table 4.6: Present Value Welfare Under En-
dogenous Entry
Change In Dollarsa % Change
Prozac profitb 21 0.8%
generic Prozac profitb 1467 99.9%
Zoloft profitb 6 0.1%
generic Zoloft profitb 1167 252.8%
‘me-too’ brand profitb -1248 -43.1%
‘me-too’ generic profitb -627 -86.2%
other non-SSRI profitb 53 0.6%
all firms’ profitb 840 3.8%
saved expenditureb 288
insurer savingsc 8258 -11.3%
consumer welfarec -84 0.4%
social welfare 9301 8.1%
a Dollars are in millions and discounted to January 1991.
b Firms’ profits are discounted at 11%.
c Insurer savings and consumer welfare are discounted at
5%.
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Appendix A
Appendix for Chapter 2
A.1 Demand Equation
Suppose consumers choose from an assortment of products which belong to two levels
of groupings. Let g index the upper level and mg index the lower, subgroup level. The
indirect utility that consumer i gets from product j at time t is given by
uijt  δjt   ψijt
where δjt  xjtβj   αp
φ
jt   γlnpamgtq   ξjt
and ψijt  ζigt   p1  σgqζimgt   p1  σgqp1  σmgqεijt.
I now define η  r1  p1  σgqp1  σmgqs P r0, 1q and so,
σmg  1 
1  η
1  σg
. (A.1)
The market share of product j as a fraction of the total lower-nesting group is equivalent
to the probability of a consumer purchasing a product from among those in the subgroup
mg:
sj{mg 
eδj{p1ηq
Dm
where Dm 
¸
kPJmg
eδk{p1ηq. (A.2)
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Similarly, the market share of subgrouping mg as a fraction of the total upper-nesting
group is equivalent to the probability that a consumer purchases from among the product
within subgrouping mg from among those in group g
smg 
D
p1σmg q
m
Dg
where Dg 
¸
kPJg
D
p1σmg q
m . (A.3)
Next, the probability that a consumer chooses a product from grouping g from among all
products is given by
sg 
D
p1σgq
g
D
where D 
¸
kPJ
D
p1σgq
g . (A.4)
Finally, the probability of the consumer choosing the outside option and not purchasing
any of the products in the market is given by
s0 
1
D
. (A.5)
The overall market share for product j is
sj  sj{mg  smg  sg
 eδj{p1ηqD
σmg
m D
σg
g D
1. (A.6)
Taking natural logs of this equation and substituting in the natural log of (5) gives
lnpsjq 
δj
1  η
 σmg lnpDmq  σglnpDgq   lnps0q. (A.7)
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Rearranging this equation and combining it with the natural logs of (2) and (3) allows for
the following steps:
lnpsjq  lnps0q 
δj
1  η
 σg

p1  σmgqlnpDmq  lnpsmgq

 σmg lnpDmq

δj
1  η
  σglnpsmgq 

σmg   σgp1  σmgq

lnpDmq

δj
1  η
  σglnpsmgq  ηlnpDmq

δj
1  η
  σglnpsmgq  η

δj
1  η
 lnpsj{mgq

 δj   σglnpsmgq   ηlnpsj{mgq. (A.8)
A.2 Elasticities
The price elasticity, ηelastsj ,ck , is the sensitivity of product j’s market share to changes in
product k’s copay:
ηelastsj ,ck 
Bsj
Bck

ck
sj
(A.9)
where sj  sj{mg  smg  sg  e
δj{p1ηqD
σmg
m D
σg
g D
1.
For j  k,
Bsj
Bcj

α
1  η
D
σmg
m D
σg
g D
1eδj{p1ηq
 σmg
α
1  η
e2δj{p1ηqD
σmg1
m D
σg
g D
1
 σgp1  σmgq
α
1  η
e2δj{p1ηqD
2σmg
m D
σg1
g D
1
 p1  σgqp1  σmgq
α
1  η
e2δj{p1ηqD
2σmg
m D
2σg
g D
2

α
1  η

sj  σmgsj{mgsj  σgp1  σmgqsj{mgsmgsj  p1  ηqsjsj


α
1  η
sj

1  σmgsj{mg  σgp1  σmgqsj{mgsmg  p1  ηqsj

. (A.10)
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For j  k, but mj  mk,
Bsj
Bck
 σmg
α
1  η
eδk{p1ηqeδj{p1ηqD
σmg1
m D
σg
g D
1
 σgp1  σmgq
α
1  η
eδk{p1ηqeδj{p1ηqD
2σmg
m D
σg1
g D
1
 p1  σgqp1  σmgq
α
1  η
eδk{p1ηqeδj{p1ηqD
2σmg
m D
2σg
g D
2
 
α
1  η

σmgsk{mgsj   σgp1  σmgqsk{mgsmgsj   p1  ηqsksj

 
α
1  η
sj

σmgsk{mg   σgp1  σmgqsk{mgsmg   p1  ηqsk

(A.11)
For mj  mk, but gj  gk,
Bsj
Bck
 
α
1  η
sj

σgp1  σmgqsk{mgsmg   p1  ηqsk

(A.12)
For gj  gk,
Bsj
Bck
 αsksj (A.13)
The own-price elasticity is then
ηown 
α
1  η
cjt

1  σmgsjt{mg  σgp1  σmgqsjt{mgsmgt  p1  ηqsjt

. (A.14)
For the analysis in this paper, the most meaninful cross-price elasticities are those within
a therapeutic class, but across molecules (lower level nests) and those across therapeutic
classes (upper level nests):
ηx-molec.  
α
1  η
cjt

σgp1  σmgqskt{mgsmgt   p1  ηqskt

and (A.15)
ηx-class  αcjtsjt, (A.16)
respectively.
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Appendix B
Appendix for Chapter 3
B.1 Derivation of Micro Moments
We begin by denoting the probability of contracting the disease treated by H2s or
PPIs by φ and the probability of becoming well by ψ. These probabilities are assumed
to be independent of consumer demographics and unobserved types. If w denotes the
probability of being well, then w  ψψ φ .
1 Suppose there are two types of consumers and
τ denotes the proportion of those who are type 2. Let p1t and p2t denote the probabilities of
buying a product on the market at time t for consumers of type 1 and type 2, respectively.
Starting with the set of moments of buying versus not buying any products on the
market, the probability purchasing at t  1 conditional on purchasing at t is then:
Prpdt 1  1|dt  1q 
Prpdt  1, dt 1  1q
Prpdt  1q

p1  wqp1  ψqpp1  τqp1tp1t 1   τp2tp2t 1q
p1  wqpp1  τqp1t   τp2tq

p1  ψqpp1  τqp1tp1t 1   τp2tp2t 1q
pp1  τqp1t   τp2tq
.
If we then denote a consumer’s health by ht (1 is healthy and 0 is sick) and the
1 Notice that 1  w is the prevalence of the disease.
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probability purchasing at t  2 conditional on purchasing at t is:
Prpdt 2  1|dt  1q 
Prpdt  1, dt 2  1|ht 1  0q   Prpdt  1, dt 2  1|ht 1  1q
Prpdt  1q

Prpdt  1, dt 1  1, dt 2  1q   Prpdt  1, dt 1  0, dt 2  1q
Prpdt  1q
 
Prpdt  1, dt 2  1|ht 1  1q
Prpdt  1q

p1  wqp1  ψq2rp1  τqp1tp1t 1p1t 2   τp2tp2t 1p2t 2s
Prpdt  1q
 
p1  wqp1  ψq2rp1  τqp1tp1  p1t 1qp1t 2   τp2tp1  p2t 1qp2t 2s
Prpdt  1q
 
p1  wqψφrp1  τqp1tp1t 2   τp2tp2t 2s
Prpdt  1q

p1  wqrp1  ψq2   ψφsrp1  τqp1tp1t 2   τp2tp2t 2s
p1  wqpp1  τqp1t   τp2tq
.
If we accept that p1t 2  p1t 1 and p2t 2  p2t 1, then
Prpdt 2  1|dt  1q 
p1  wqrp1  ψq2   ψφsrp1  τqp1tp1t 1   τp2tp2t 1s
Prpdt  1q

rp1  ψq2   ψφsp1  wqp1  ψqrp1  τqp1tp1t 1   τp2tp2t 1s
p1  ψqPrpdt  1q

rp1  ψq2   ψφs
p1  ψq
Prpdt 1  1|dt  1q where φ  ψ
1  w
w
.(B 1)
This equation then allows us to calculate the unknowns, ψ and φ.
The probability of purchasing at t  1 and t  2 conditional on purchasing at t is:
Prpdt 1  1, dt 2  1|dt  1q 
Prpdt  1, dt 1  1, dt 2  1q
Prpdt  1q

p1  wqp1  ψq2rp1  τqp1tp1t 1p1t 2   τp2tp2t 1p2t 2s
p1  wqpp1  τqp1t   τp2tq

p1  ψq2rp1  τqp1tp1t 1p1t 2   τp2tp2t 1p2t 2s
pp1  τqp1t   τp2tq
.
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Now, we move on to the set of moments specific to the product characteristics denoted
by k. Let pk1t and p
k
2t denote the probabilities of buying a product with characteristic k
on the market at time t for consumers of type 1 and type 2, respectively. The probability
of purchasing a product with characteristic k at t  1 conditional on purchasing a product
with characteristic k at t is:
Prpdkt 1  1|d
k
t  1q 
Prpdkt  1, d
k
t 1  1q
Prpdkt  1q

p1  wqp1  ψqpp1  τqpk1tp
k
1t 1   τp
k
2tp
k
2t 1q
p1  wqpp1  τqpk1t   τp
k
2tq

p1  ψqpp1  τqpk1tp
k
1t 1   τp
k
2tp
k
2t 1q
p1  τqpk1t   τp
k
2t
.
The probability of purchasing any product at time t and a product with characteristic
k at t  2 conditional on purchasing a product with characteristic k at t is:
Prpdt 1  1, d
k
t 2  1|d
k
t  1q 
Prpdkt  1, dt 1  1, d
k
t 2  1q
Prpdkt  1q

p1  wqp1  ψq2pp1  τqpk1tp1t 1p
k
1t 2   τp
k
2tp2t 1p
k
2t 2q
p1  wqpp1  τqpk1t   τp
k
2tq

p1  ψq2pp1  τqpk1tp1t 1p
k
1t 2   τp
k
2tp2t 1p
k
2t 2q
p1  τqpk1t   τp
k
2t
.
Finally, the probability of purchasing a product with characteristic k at time t and t 2
conditional on purchasing a product with characteristic k at t is:
Prpdkt 1  1, d
k
t 2  1|d
k
t  1q 
Prpdkt  1, d
k
t 1  1, d
k
t 2  1q
Prpdkt  1q

p1  wqp1  ψq2pp1  τqpk1tp
k
1t 1p
k
1t 2   τp
k
2tp
k
2t 1p
k
2t 2q
p1  wqpp1  τqpk1t   τp
k
2tq

p1  ψq2pp1  τqpk1tp
k
1t 1p
k
1t 2   τp
k
2tp
k
2t 1p
k
2t 2q
p1  τqpk1t   τp
k
2t
.
The micro moments calculated from the MarketScan data are presented in Table B.1.
Using the equation B.1 and the first set of moments in Table B.1, we are able to calculate
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φ and ψ, as presented in Table B.2. Noting that the values for the period 1996 to 2004
greatly differ from those in the period 2005 to 2009, we believe this implies consumers
are recovering faster from uclers and other related health problems. Assuming the same
probability of contracting the disease treated by H2s and PPIs, φ2, we can then calculate
a new probability of becoming well, ψ2, as well as a new prevalence rate of having the
disease, prev2.
Table B.1: Moments from MarketScan
Dimension Moments Avg. 1996–2004 2005-2009
Buy vs Not Buy Prpdt 1  1|dt  1q 0.7495 0.7401 0.7665
Prpdt 2  1|dt  1q 0.7003 0.7033 0.6948
Prpdt 1  1, dt 2  1|dt  1q 0.611 0.6063 0.6195
H2 vs PPI PrpdHt 1  1|d
H
t  1q 0.6482 0.6530 0.6398
Prpdt 1  1, dHt 2  1|d
H
t  1q 0.4929 0.5057 0.4700
PrpdHt 1  1, d
H
t 2  1|d
H
t  1q 0.4859 0.5003 0.4599
PrpdPt 1  1|d
P
t  1q 0.7599 0.7525 0.7731
Prpdt 1  1, dPt 2  1|d
P
t  1q 0.6244 0.6219 0.6291
PrpdPt 1  1, d
P
t 2  1|d
P
t  1q 0.6213 0.6180 0.6274
Brand vs Generic PrpdBt 1  1|d
B
t  1q 0.7485 0.7421 0.7601
Prpdt 1  1, dBt 2  1|d
B
t  1q 0.6085 0.6069 0.6115
PrpdBt 1  1, d
B
t 2  1|d
B
t  1q 0.6065 0.6049 0.6093
PrpdGt 1  1|d
G
t  1q 0.6778 0.6417 0.743
Prpdt 1  1, dGt 2  1|d
G
t  1q 0.5272 0.4917 0.591
PrpdGt 1  1, d
G
t 2  1|d
G
t  1q 0.5229 0.4866 0.5881
Capsule vs Tablet PrpdCt 1  1|d
C
t  1q 0.5052 0.5409 0.441
Prpdt 1  1, dCt 2  1|d
C
t  1q 0.4662 0.4922 0.4194
PrpdCt 1  1, d
C
t 2  1|d
C
t  1q 0.3664 0.3959 0.3134
PrpdTt 1  1|d
T
t  1q 0.4661 0.4765 0.4474
Prpdt 1  1, dTt 2  1|d
T
t  1q 0.4158 0.4242 0.4007
PrpdTt 1  1, d
T
t 2  1|d
T
t  1q 0.3229 0.3318 0.307
Table B.2: Probabilites of Ulcers
Avg. 1996–2004 2005-2009
ψ 0.0668 0.0506 0.0961
φ 0.0167 0.0126 0.0240
φ2 0.0126 0.0126 0.0126
ψ2 0.0664 0.0506 0.0949
prev2 0.1708 0.2000 0.1183
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B.2 Elasticities
Let s
rinss
j and s
runinss
j denote the respective shares of product j among consumers who
are insured and uninsured. The share that firm f sees for its product j is then given by:
sj  ρs
rinss
j   p1  ρqs
runinss
j
 ρ
exp pαbpaj  Xβq°
l exp pδ
rinss
l q
  p1  ρq
exp pαpj  Xβq°
l exp pδ
runinss
l q
where the copay equation is given by cj  bp
a
j .
The partial derivative of sj with respect to pj is then given by:
Bsj
Bpj
 ραbapa1j
exp pαbpaj  Xβq°
l exp pδ
rinss
l q
 ραbapa1j exp pαbp
a
j  Xβq
exp pαbpaj  Xβq
p
°
l exp pδ
rinss
l qq
2
 p1  ρqα
exp pαpj  Xβq°
l exp pδ
runinss
l q
 p1  ρqα exp pαpj  Xβq
exp pαpj  Xβq
p
°
l exp pδ
runinss
l qq
2
 ραbapa1j s
rinss
j  ραbap
a1
j s
rinss
j s
rinss
j   p1  ρqαs
unins
j  p1  ρqαs
unins
j s
unins
j
 ραbapa1j s
rinss
j p1  s
rinss
j q   p1  ρqαs
runinss
j p1  s
runinss
j q
The partial derivative of sj with respect to pk is then given by:
Bsj
Bpk
 ραbapa1k exp pαbp
a
k  Xβq
exp pαbpaj  Xβq
p
°
l exp pδ
rinss
l qq
2
p1  ρqα exp pαpk  Xβq
exp pαpj  Xβq
p
°
l exp pδ
runinss
l qq
2
 ραbapa1k s
rinss
k s
rinss
j  p1  ρqαs
runinss
k s
runinss
j
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If we then follow the elasticity equations, we get:
ηown 
Bsj
Bpj
pj
sj


ραbapa1j s
rinss
j p1  s
rinss
j q   p1  ρqαs
runinss
j p1  s
runinss
j q
 pj
sj
ηcross 
Bsj
Bpk
pk
sj


ραbapa1k s
rinss
k s
rinss
j  p1  ρqαs
runinss
k s
runinss
j
 pk
sj
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